

## STATEMENT

We, ACON Laboratories, Inc., having a registered office at *5850 Oberlin Drive #340, San Diego, CA 92121* authorize SRL Sanmedico having a registered office at *A. Corobceanu street 7A, apt. 9, Chisinau, MD-2012, Moldova*

to register, notify, renew or modify the registration of medical devices on the territory of the Republic of Moldova.

Date: March 18, 2024

Signature:



---

Qiyi Xie, Md, MPH  
V.P. of Regulatory & Clinical Affairs  
ACON Laboratories, Inc.



# Certificate

No. Q5 104507 0001 Rev. 03

**Holder of Certificate:** **ACON Laboratories, Inc.**  
5850 Oberlin Drive, #340  
San Diego CA 92121  
USA

**Certification Mark:**



**Scope of Certificate:** **Design and Development, Manufacture and distribution of In Vitro Diagnostic Test Kits and Reagents for the Determination of Infectious Diseases, Clinical Chemistry, Drugs of Abuse, Tumor/Cardiac Marker, Fertility/Pregnancy and Blood Glucose Monitoring System, Lancing Devices and Lancets**

The Certification Body of TÜV SÜD Product Service GmbH certifies that the company mentioned above has established and is maintaining a quality management system, which meets the requirements of the listed standard(s). All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: [www.tuvsud.com/ps-cert?q=cert:Q5 104507 0001 Rev. 03](http://www.tuvsud.com/ps-cert?q=cert:Q5 104507 0001 Rev. 03)

**Report No.:** SH22743A01

**Valid from:** 2022-09-15  
**Valid until:** 2025-09-06

**Date,** 2022-09-15

Christoph Dicks  
Head of Certification/Notified Body

# Certificate

No. Q5 104507 0001 Rev. 03

**Applied Standard(s):**

EN ISO 13485:2016  
Medical devices - Quality management systems -  
Requirements for regulatory purposes  
(ISO 13485:2016)  
DIN EN ISO 13485:2016

**Facility(ies):**

**ACON Laboratories, Inc.**  
**5850 Oberlin Drive, #340, San Diego CA 92121, USA**

Address holder for registration only

**ACON Laboratories, Inc.**  
**10125 Mesa Rim Road, San Diego CA 92121, USA**

Manufacture and distribution of  
In Vitro Diagnostic Test Kits and Reagents for the Determination of  
Infectious Diseases, Clinical Chemistry, Drugs of Abuse,  
Tumor/Cardiac Marker, Fertility/Pregnancy and Blood Glucose  
Monitoring System, Lancing Devices and Lancets

**ACON Laboratories, Inc.**  
**6865 Flanders Dr., Suite B, San Diego CA 92121, USA**

Storage of  
In Vitro Diagnostic Test Kits and Reagents for the Determination of  
Infectious Diseases, Clinical Chemistry, Drugs of Abuse,  
Tumor/Cardiac Marker, Fertility/Pregnancy and Blood Glucose  
Monitoring System, Lancing Devices and Lancets

**AZURE Institute, Inc.**  
**10125 Mesa Rim Road, San Diego CA 92121, USA**

Design and Development of  
In Vitro Diagnostic Test Kits and Reagents for the Determination of  
Infectious Diseases, Clinical Chemistry, Drugs of Abuse,  
Tumor/Cardiac Marker, Fertility/Pregnancy and Blood Glucose  
Monitoring System, Lancing Devices and Lancets

**Acon Laboratories Inc.**  
**Guerrero Negro 9942 Parque Industrial Pacifico IV, 22644**  
**Tijuana B.C. CP, MEXICO**

Manufacture of  
blood glucose test strips, antigen rapid test and IgG/IgM antibody  
rapid test for infectious disease.



Benannt durch/Designated by  
Zentralstelle der Länder  
für Gesundheitsschutz  
bei Arzneimitteln und  
Medizinprodukten  
www.zlg.de  
ZLG-BS-245.10.07



Product Service

# EC Certificate

Full Quality Assurance System

Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex IV excluding (4, 6)  
(List A and B and devices for self-testing)

**No. V1 104507 0003 Rev. 06**

**Manufacturer:**

**ACON Laboratories, Inc.**

5850 Oberlin Drive, #340  
San Diego CA 92121  
USA

**Product Category(ies): Blood glucose measuring systems for self testing  
and self-testing devices for clinical chemistry,  
hematology and pregnancy and ovulation**

The Certification Body of TÜV SÜD Product Service GmbH declares that the aforementioned manufacturer has implemented a quality assurance system for design, manufacture and final inspection of the respective devices / device families in accordance with IVDD Annex IV. This quality assurance system conforms to the requirements of this Directive and is subject to periodical surveillance. For marketing of List A devices an additional Annex IV (4) certificate is mandatory. All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: [www.tuvsud.com/ps-cert?q=cert:V1 104507 0003 Rev. 06](http://www.tuvsud.com/ps-cert?q=cert:V1_104507_0003_Rev.06)

**Report no.:**

SH22743EXT01

**Valid from:**

2022-05-04

**Valid until:**

2025-05-26

**Date,**

2022-05-04

Christoph Dicks  
Head of Certification/Notified Body



# EC Certificate

Full Quality Assurance System

Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex IV excluding (4, 6)  
(List A and B and devices for self-testing)

**No. V1 104507 0003 Rev. 06**

## Model(s):

On Call Plus Blood Glucose Monitoring System,  
On Call Plus Blood Glucose Test Strips,  
On Call EZ II Blood Glucose Monitoring System,  
On Call Advanced Blood Glucose Monitoring System,  
On Call Advanced Blood Glucose Test Strips,  
On Call Chosen Blood Glucose Test Strips,  
On Call Vivid Blood Glucose Monitoring System (OGM-101),  
On Call Vivid Blood Glucose Test Strips (OGS-101),  
On Call Sharp Blood Glucose Monitoring System (OGM-121),  
On Call Sharp Blood Glucose Test Strips (OGS-121)  
On Call Plus II Blood Glucose Monitoring System (OGM-171),  
On Call Plus II Blood Glucose Test Strips (OGS-171),  
On Call Extra Blood Glucose Monitoring System (OGM-191),  
On Call Extra Blood Glucose Test Strips (OGS-191),  
On Call GK Dual Blood Glucose & Ketone Monitoring System (OGM-161),  
On Call Blood Ketone Test Strips (OGS-161),  
Urinalysis Reagent Strips (Urine),  
UTI Urinary Tract Infection Test Strips,  
Cholesterol Monitoring System (CCM-111),  
CHOL Total Cholesterol Test Devices (CCS-111),  
TRIG Triglycerides Test Devices (CCS-112),  
HDL High Density Lipoprotein Test Devices (CCS-113),  
3-1 Lipid Panel Test Devices (CCS-114),  
Cholesterol CTRL Control Devices,  
Cholesterol Monitoring System (CCM-101),  
CHOL Total Cholesterol Test Strips (CCS-101),  
PT/INR Monitoring System (CCM-151),  
PT/INR Test Strips (CCS-151),  
Hemoglobin Testing System (CCM-141),  
Hemoglobin Test Strips (CCS-141),  
hCG Pregnancy Rapid Test Cassette (Urine),  
Pregnancy Rapid Test Midstream,  
On Call Extra Mobile Blood Glucose Monitoring System (OGM-281),  
On Call Sure Blood Glucose Monitoring System (OGM-211),  
On Call Sure Sync Blood Glucose Monitoring System (OGM-212),  
On Call Sure Blood Glucose Test Strips (OGS-211),  
GIMA Blood Glucose Monitoring System,  
GIMA Bluetooth Blood Glucose Monitoring System,  
GIMA Blood Glucose Test Strips,  
On Call GU Dual Blood Glucose & Uric Acid Monitoring



# EC Certificate

Full Quality Assurance System

Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex IV excluding (4, 6)  
(List A and B and devices for self-testing)

**No. V1 104507 0003 Rev. 06**

System (OGM-201),  
On Call Blood Uric Acid Test Strips (OGS-201),  
LH Ovulation Rapid Test Cassette (Urine),  
Ovulation Rapid Test Midstream,  
Ovulation & Pregnancy Test Combo Pack,  
On Call Extra Voice Blood Glucose Monitoring System  
(OGM-291),  
Early Detection Pregnancy Test,  
Digital Pregnancy Test,  
Go-Keto Blood Glucose & Ketone Monitoring System (OGM-  
161),  
Go-Keto Blood Ketone Test Strips (OGS-161),  
Go-Keto Blood Glucose Test Strips,  
On Call Extra GM Blood Glucose Monitoring System(OGM-  
191),  
On Call Extra GM Blood Glucose Test Strips (OGS-191),  
On Call Plus GM Blood Glucose Monitoring System,  
On Call Plus GM Blood Glucose Test Strips,  
Go-Keto Urinalysis Reagent Strips

## Facility(ies):

ACON Laboratories, Inc.  
5850 Oberlin Drive, #340, San Diego CA 92121, USA

ACON Laboratories, Inc.  
10125 Mesa Rim Road, San Diego CA 92121, USA

AZURE Institute, Inc.  
10125 Mesa Rim Road, San Diego CA 92121, USA

Acon Laboratories Inc.  
Guerrero Negro 9942 Parque Industrial Pacifico IV, 22644 Tijuana  
B.C. CP, MEXICO

## Declaration of Conformity

ACON Laboratories, Incorporated  
5850 Oberlin Drive #340  
San Diego, CA 92121, USA

**We, the manufacturer, declare under our sole responsibility that the  
*in vitro* diagnostic device:**

*Mission*® Urinalysis Reagent Strips (U031-XX1)

**classified as Others in the directive 98/79/EC,**

**meets all the provisions of the directive 98/79/EC on *in vitro* diagnostic  
medical devices which apply to it**

**The self-declaration is according to Annex III  
(excluding Section 6) of the Directive.**

Authorized Representative:  
Medical Device Safety Service GmbH  
Schiffgraben 41  
30175 Hannover, Germany

Signed this 11 day of February, 2020  
in San Diego, CA USA



---

Qiyi Xie, MD, MPH  
Senior Staff, Regulatory Affairs & Clinical Affairs  
Acon Laboratories, Inc.





# Mission® Urinalysis Reagent Strips and Urine Analyzers

Obtain reliable and cost-effective results with *Mission®* Urinalysis Reagent Strips and Urine Analyzers!

- *Accurate*
- *Reliable*
- *Convenient*



Global Diagnostics for Local Markets™



# Urinalysis Reagent Strips

## Simple and Accurate


- Analytical sensitivity better than or comparable to market leaders
- High quality color chart ensures accurate visual reading

## Flexible


- Compatible for visual and analyzer reading
- More than 30 different combinations available

## Multiple Packaging Options and Long Shelf Life


- Canister Packaging
  - Available in 25, 50, 100 and 150 strips per kit
  - 2 year shelf life for unopened canisters which offers cost savings and convenience for high volume testing
  - 3 month shelf life for strips in opened canisters
- Pouch Packaging *New!*
  - Single-strip Pouch
    - Individually packaged strips with 1, 3, 6 and 20 strips and 1 color chart per kit for OTC or low volume testing
    - Unique packaging maintains 2 year shelf life for all strips in the kit compared to 3 months for remaining strips in an opened canister
  - Multi-strip Pouch
    - Canister Refill Kits with 25 strips/pouch uniquely packaged to save cost for low volume testing and extended shelf life by using the canister for refills



Step 1: Immerse strip into urine



Step 2: Remove excess urine



Step 3: Obtain results by analyzer or visual reading

Catalog No.	No. of Parameters	Type of Strip <sup>♦</sup>		Strips per Canister <sup>°</sup>	Pouch Packaging <sup>▲</sup>	Reading Method			Analyzer-Read Strips: Standard (S) or Additional (A)	Parameters													
		For Visual Reading	For Analyzer Reading (U120/U500)			Visual	U120	U500		ASC	GLU	BIL	KET	SG	BLO	pH	PRO	URO	NIT	LEU	ALB	CRE	
U031-131	13	13C	NA	100 <sup>■</sup>	✓	✓	NA	NA	A	*	*	*	*	*	*	*	*	*	*	*	*	*	*
U031-111	11	11A		100	✓	✓	✓	✓	S	*	*	*	*	*	*	*	*	*	*	*	*		
U031-101	10	10U		100	✓	✓	✓	✓	S		*	*	*	*	*	*	*	*	*	*	*		
		10A				✓	✓	✓	A	*	*	*	*	*	*	*	*	*	*	*	*		
		10C				✓	✓	✓	S		*	*	*	*	*	*	*	*	*	*	*	*	*
U031-091	9	9U		100	✓	✓	✓	✓	S		*	*	*	*	*	*	*	*	*	*			
U031-081	8	8U		100	✓	✓	✓	✓	A		*	*	*	*	*	*	*	*	*	*			
		8N				✓	✓	✓	S		*	*	*	*	*	*	*	*	*	*			
		8S				✓	✓	✓	A		*	*	*	*	*	*	*	*	*	*	*		
U031-071	7	7N		100	✓	✓	✓	✓	A		*		*		*	*	*		*	*			
U031-061	6	6N	6NE	100	✓	✓	✓	✓	A		*				*	*	*		*	*			
		6U	6UE			✓	✓	✓				*		*	*		*	*	*				
U031-051	5	5B	5BE	100	✓	✓	✓		A		*		*		*	*	*						
		5N	5NE			✓	✓	✓			*				*	*	*		*	*			
		5S	5SE			✓	✓				*		*	*	*	*							
		5U	5UE			✓	✓				*	*		*	*	*	*	*	*	*			
U031-041	4	4S	4SE	100	✓	✓	✓	✓	A		*			*		*	*						
		4B	4BE			✓	✓				*		*	*	*								
		4K	4KE			✓	✓	✓			*		*		*	*				*			
		4G	4GE			✓	✓				*		*	*	*				*				
		4N	4NE			✓	✓	✓			*		*	*	*	*	*	*	*	*			
		4P	4PE			✓	✓	✓			*		*	*	*	*	*	*	*	*	*		
U031-031	3	3P	3PE	100	✓	✓	✓	✓	A		*				*	*							
		3K	3KE			✓	✓	✓			*		*		*								
		3G	3GE			✓	✓	✓			*		*		*								
		3N	3NE			✓	✓	✓			*		*		*		*	*	*	*			
U031-021	2	2G	2GE	100	✓	✓	✓	✓	A		*				*	*							
		2K	2KE			✓	✓	✓			*		*		*					*			
		2N	2NE			✓	✓	✓			*		*		*				*				
		2B	2BE			✓	✓	✓			*		*		*								
		2U	2UE			✓	✓	✓			*		*		*			*	*				
		2S	2SE			✓	✓	✓			*		*		*			*	*				
		2C	2CE	100 <sup>■</sup>	✓	✓	✓		*		*		*					*	*				
U031-011	1	1B	1BE	100	✓	✓	✓		A					*									
		1P	1PE			✓	✓	✓					*										
		1G	1GE			✓	✓	✓			*				*								
		1K	1KE			✓	✓	✓					*										
		1R	1RE			✓	✓	✓					*			*							

♦ Type of Strip:  
Visual Strip Size  
1-6 Parameters: 5 mm x 80 mm; 7-11 Parameters: 5 mm x 108 mm;  
12-13 Parameters: 5 mm x 121 mm  
U120/U500 Strip Size  
1-11 Parameters: 5 mm x 108 mm;  
"E" means extended strip length for 1-6 Parameters

♦ Also available in canisters of 25, 50 and 150 strips.  
■ Not available in canisters of 150 strips  
▲ Single-strip Pouch available in 1, 3, 6 and 20 strip kit  
Canister Refill Kit, with 25 strips per pouch or canister, available in 3-pouch and 1- canister kit, or 4-pouch kit

CE Marked for sale in the European Community  
Cleared for US 510(k)



# U120 Urine Analyzer



## Accurate

- Up to 120 tests/hour in Continuous Test Option
- Capable of reading 1 strip at a time in Single Test Option
- Test modes include Routine, STAT and QC
- Automatic calibration for accurate results and easy operation

## Reliable

- Can read up to 4 Strip combinations with 8, 9, 10, 11 parameters, additional strips with 1-11 parameters available upon request
- Minimal training required

## Convenient Operation

- Saves and recalls the last 2,000 results automatically
- Audible beep signals operator to dip strips in urine
- Can print up to 3 copies per test for convenient reviewing and easy record keeping
- Option to print results on sticker paper for quick and simple record management

## Easy Data Management

- Includes RS232C port for easy data transfer to an external computer or LIS
- Optional Barcode Reader to record patient ID

## Unique Lockout Functions *new!*

- Strip Lockout
  - Prevents using strips of another brand on the U120 Urine Analyzer
  - Requires barcode reader scan or manual entry of the canister code
- User Lockout
  - Eliminates unapproved users from testing
  - Up to 10 lab operators can perform testing, but only the lab administrator can change analyzer settings
- QC Lockout
  - Prevents testing without passing QC
  - QC tests can be performed once every 8 hours, day, week or month
  - Analyzer will alert when to run QC test
  - If QC tests fail, analyzer will switch to STAT mode and list "E" at the end of each test number

## Specifications

Feature	Specifications
Analyzer Type	Manual
Methodology	Reflectance Photometry
Detection	Photosensitive Diode
Throughput	Single Test Option: 60 tests/hour Continuous Test Option: 120 tests/hour
Test Modes	Routine, STAT and QC
Lockout Functions	Strip Lockout: Available Upon Request; User/QC Lockout: Included with option to turn ON/OFF
Memory	Last 2,000 results
Strip Incubation Time	1 Minute
Wavelength of Monochromatic LED	525 nm and 635 nm
Standard Strips	8, 9, 10, 11 Parameters (5 mm x 108 mm)
Additional Strips Available	1-11 Parameters (5 mm x 108 mm); see URS Parameters
Total Combinations Per Analyzer	4 Combinations
Analyzer Ports	Standard RS232C Port for Barcode Reader or Data Transfer USB Port for Data Transfer 25 Pin Parallel Port for External Printer
Capabilities	Internal Thermal Printer (included)      RS232C Barcode Reader (optional) Optional External Printer (not included)      USB or RS232C Data Transfer Cable (optional)
Major Readable Barcodes	Code 128, Code 39, Codabar (NW-7), Interleaved 25, UPC-A, UPC-E, EAN 8, EAN 13
Calibration	Automatic
Available Languages on the Screen	English and additional language(s)
Operating Conditions	0-40°C (32-104°F); ≤ 85% RH
Storage Conditions	-5-50°C (23-122°F); ≤ 90% RH
Power Source	100-240 VAC, 50-60 Hz
Dimensions (L x W x H)	27.2 cm x 26.9 cm x 14.6 cm (10.7" x 10.6" x 5.7")
Display Dimensions (L x W)	10.8 cm x 5.7 cm (4.2" x 2.2")
Weight	2.6 kg (5.7 lbs)

## Ordering Information

Product Name	Catalog No.	Components		Kit Box Dimensions (L x W x H) & Weight	Carton Dimensions (L x W x H) & Weight	Number of Kits/Carton
U120 Urine Analyzer	U111-101 <sup>†</sup>	1 Urine Analyzer 1 Strip holder 2 Printer Paper Rolls	2 Fuses (2.0A) 1 Power Cord 1 Quick Start Guide 1 Instruction Manual	42.0 cm x 41.5 cm x 31 cm; 5.0 kg		1
U120 Urine Analyzer with Barcode Reader	U111-111 <sup>†</sup>	1 Urine Analyzer 1 Strip holder 2 Printer Paper Rolls 1 Barcode Reader (RS232C)	2 Fuses (2.0A) 1 Power Cord 1 Serial Splitter Cable (RS232C) 1 Quick Start Guide 1 Instruction Manual	44.5 cm x 44.5 cm x 40.0 cm; 5.5 kg		1
Barcode Reader	U221-111 <sup>†</sup>	1 Barcode Reader (RS232C)	1 Serial Splitter Cable (RS232C)	23.6 cm x 10.8 cm x 7.8 cm; 0.482 kg 9.3" x 4.3" x 3.1"; 17.0 oz	63.0 cm x 37.0 cm x 30.0 cm; 12.0 kg 24.8" x 14.6" x 11.8"; 423.3 oz	22
Printer Paper Rolls	U121-101	4 Printer Paper Rolls	Thermal Paper (0.06 m x 20 m): 200 results/roll Sticker Paper (0.06 m x 9 m): 100 results/roll	12.0 cm x 12.0 cm x 6.5 cm; 0.36 kg 4.7" x 4.7" x 2.6"; 12.7 oz	63.0 cm x 37.0 cm x 30.0 cm; 19.4 kg 24.8" x 14.6" x 11.8"; 684.3 oz	50
U120 Data Transfer Kit	U221-131 <sup>†</sup>	1 Data Transfer Cable (RS232C)	1 Package Insert	12.0 cm x 12.0 cm x 6.5 cm; 0.4 kg 4.7" x 4.7" x 2.6"; 14.1 oz	63.0 cm x 37.0 cm x 30.0 cm; 21.4 kg 24.8" x 14.6" x 11.8"; 684.3 oz; 754.9 oz	8



# U500 Urine Analyzer



## Accurate and Efficient

- Up to 500 tests/hour for medium/large volume sample testing
- Professional accuracy equivalent to market leader
- Automatic strip detection and alignment for better efficiency
- Test modes include Routine, STAT and QC

## Easy to Operate

- Large touch screen LCD offers simple menu navigation
- Uniquely designed strip platform/waste tray unit for easy one-step cleaning

## Convenient

- Automatic calibration and waste disposal reduce hands-on time
- Can read strips with 8, 9, 10, 11 parameters, additional strips with 1-11 parameters available upon request
- Strip selection of up to 4 combinations for analyzer reading
- Stores up to 2,000 records and automatically flags abnormal results
- Capable of printing results on sticker paper for quick and easy record management

## Data Management Capability

- Includes RS232C port for easy data transfer to an external computer or LIS
- Optional Barcode Reader to record patient ID

## Unique Lockout Functions Coming Soon!

- Strip Lockout
  - Prevents using strips of another brand on the U500 Urine Analyzer
  - Requires barcode reader scan or manual entry of the canister code
- User Lockout
  - Eliminates unapproved users from testing
  - Up to 10 lab operators can perform testing, but only the lab administrator can change analyzer settings
- QC Lockout
  - Prevents testing without passing QC
  - QC tests can be performed once every 8 hours, day, week or month
  - Analyzer will alert when to run QC test
  - If QC tests fail, analyzer will switch to STAT mode and list "E" at the end of each test number

## Specifications

Feature	Specifications
Analyzer Type	Semi-Automatic
Methodology	Reflectance Photometry
Detection	Photosensitive Diode
Throughput	500 tests/hour (Measuring cycle: 7 seconds/test)
Test Modes	Routine, STAT and QC
Lockout Functions	Strip Lockout: Available Upon Request; User/QC Lockout: Included with option to turn ON/OFF
Memory	Last 2,000 Records
Strip Incubation Time	1 Minute
Wavelength	525 and 635 nm
Standard Strips	8, 9, 10, 11 Parameters (5 mm x 108 mm)
Additional Strips Available	1-11 Parameters (5 mm x 108 mm); see URS Parameters
Total Combinations Per Analyzer	4 Combinations
Waste Disposal Capacity	Up to 150 Strips
Analyzer Ports	Standard RS232C Port for Barcode Reader or Data Transfer 25 Pin Parallel Port for External Printer
Capabilities	Internal Thermal Printer (included)      RS232C Barcode Reader (optional) Optional External Printer (not included)      RS232C Data Transfer Cable (optional)
Major Readable Barcodes	Code 128, Code 39, Codabar (NW-7), Interleaved 25, UPC-A, UPC-E, EAN 8, EAN 13
Calibration	Automatic
Available Languages on the Screen	English and additional language(s)
Operating Conditions	0-40°C (32-104°F); ≤85% RH
Storage Conditions	-5-50°C (23-122°F); ≤90% RH
Power Source	100-240 VAC, 50-60 Hz
Dimensions (L x W x H)	36.6 cm x 28.3 cm x 19.5 cm (14.4" x 11.1" x 7.7")
Display Dimensions (L x W)	11.5 cm x 9.0 cm (4.5" x 3.5")
Weight	4.0 kg (8.8 lbs)

## Ordering Information

Product Name	Catalog No.	Components	Kit Box Dimensions (L x W x H) & Weight	Carton Dimensions (L x W x H) & Weight	Number of Kits/Carton
U500 Urine Analyzer	U211-101✓	1 Urine Analyzer 1 Strip Platform/Waste Tray 2 Printer Paper Rolls	2 Fuses (2.0A) 1 Power Cord 1 Instruction Manual	51.0 cm x 42.0 cm x 38.5 cm; 7 kg 20.1" x 16.5" x 15.2"; 246.9 oz	1
U500 Urine Analyzer with Barcode Reader	U211-111✓	1 Urine Analyzer 1 Strip Platform/Waste Tray 2 Printer Paper Rolls 1 Barcode Reader (RS232C)	2 Fuses (2.0A) 1 Power Cord 1 Serial Splitter Cable (RS232C) 1 Instruction Manual	55.0 cm x 55.0 cm x 55.0 cm; 9.2 kg 21.7" x 21.7" x 21.7"; 324.5 oz	1
Barcode Reader	U221-111✓†	1 Barcode Reader (RS232C)	1 Serial Splitter Cable (RS232C)	23.6 cm x 10.8 cm x 7.8 cm; 0.482 kg 9.3" x 4.3" x 3.1"; 17.0 oz	22
Printer Paper Rolls	U121-101	4 Printer Paper Rolls	Thermal Paper (0.06 m x 20 m): 200 results/roll Sticker Paper (0.06 m x 9 m): 100 results/roll	12.0 cm x 12.0 cm x 6.5 cm; 0.360 kg 4.7" x 4.7" x 2.6"; 12.7 oz	50
U500 Data Transfer Kit	U221-131✓	1 Data Transfer Cable (RS232C)	1 Package Insert	12.0 cm x 12.0 cm x 6.5 cm; 0.40 kg 4.7" x 4.7" x 2.6"; 14.1 oz	8

**We also offer other rapid diagnostic and medical products:**

Blood Glucose Monitoring Systems, Immunoassay EIA/ELISA and more.

✓ CE Marked for sale in the European Community

† Cleared for US 510(k)



# Mission® Urinalysis Reagent Strips (Urine)

## Package Insert

REF U031-011	REF U031-051	REF U031-091	English
REF U031-021	REF U031-061	REF U031-101	
REF U031-031	REF U031-071	REF U031-111	
REF U031-041	REF U031-081		

For rapid detection of multiple analytes in human urine.  
For *in vitro* diagnostic use only.

### INTENDED USE

The Urinalysis Reagent Strips (Urine) are firm plastic strips onto which several separate reagent areas are affixed. The test is for the qualitative and semi-quantitative detection of one or more of the following analytes in urine: Ascorbic acid, Glucose, Bilirubin, Ketone (Acetoacetic acid), Specific Gravity, Blood, pH, Protein, Urobilinogen, Nitrite and Leukocytes.

### SUMMARY

Urine undergoes many changes during states of disease or body dysfunction before blood composition is altered to a significant extent. Urinalysis is a useful procedure as an indicator of health or disease, and as such, is a part of routine health screening. The Urinalysis Reagent Strips (Urine) can be used in general evaluation of health, and aids in the diagnosis and monitoring of metabolic or systemic diseases that affect kidney function, endocrine disorders and diseases or disorders of the urinary tract.<sup>1,2</sup>

### PRINCIPLE AND EXPECTED VALUES

**Ascorbic acid:** This test involves decolorization of Tillmann's reagent. The presence of ascorbic acid causes the color of the test field to change from blue-green to orange. Patients with adequate diet may excrete 2-10 mg/dL daily. After ingesting large amounts of ascorbic acid, levels can be around 200 mg/dL.

**Glucose:** This test is based on the enzymatic reaction that occurs between glucose oxidase, peroxidase and chromogen. Glucose is first oxidized to produce gluconic acid and hydrogen peroxide in the presence of glucose oxidase. The hydrogen peroxide reacts with potassium iodide chromogen in the presence of peroxidase. The extent to which the chromogen is oxidized determines the color which is produced, ranging from green to brown. Glucose should not be detected in normal urine. Small amounts of glucose may be excreted by the kidney.<sup>3</sup> Glucose concentrations as low as 100 mg/dL may be considered abnormal if results are consistent.

**Bilirubin:** This test is based on azo-coupling reaction of bilirubin with diazotized dichloroaniline in a strongly acidic medium. Varying bilirubin levels will produce a pinkish-tan color proportional to its concentration in urine. In normal urine, no bilirubin is detectable by even the most sensitive methods. Even trace amounts of bilirubin require further investigation. Atypical results (colors different from the negative or positive color blocks shown on the color chart) may indicate that bilirubin-derived bile pigments are present in the urine specimen, and are possibly masking the bilirubin reaction.

**Ketone:** This test is based on ketones reacting with nitroprusside and acetoacetic acid to produce a color change ranging from light pink for negative results to a darker pink or purple color for positive results. Ketones are normally not present in urine. Detectable ketone levels may occur in urine during physiological stress conditions such as fasting, pregnancy and frequent strenuous exercise.<sup>4-6</sup> In starvation diets, or in other abnormal carbohydrate metabolism situations, ketones appear in the urine in excessively high concentration before serum ketones are elevated.<sup>7</sup>

**Specific Gravity:** This test is based on the apparent pKa change of certain pretreated polyelectrolytes in relation to ionic concentration. In the presence of an indicator, colors range from deep blue-green in urine of low ionic concentration to green and yellow-green in urine of increasing ionic concentration. Randomly collected urine may vary in specific gravity from 1.003-1.035.<sup>8</sup> Twenty-four hour urine from healthy adults with normal diets and fluid intake will have a specific gravity of 1.016-1.022.<sup>9</sup> In cases of severe renal damage, the specific gravity is fixed at 1.010, the value of the glomerular filtrate.

**Blood:** This test is based on the peroxidase-like activity of hemoglobin which catalyzes the reaction of diisopropylbenzene dihydroperoxide and 3,3',5,5'-tetramethylbenzidine. The resulting color ranges from orange to dark blue. Any green spots or green color development on the reagent area within 60 seconds is significant and the urine specimen should be examined further. Blood is often, but not invariably, found in the urine of menstruating females. The significance of a trace reading varies among patients and clinical judgment is required in these specimens.

**pH:** This test is based on a double indicator system which gives a broad range of colors covering the entire urinary pH range. Colors range from orange to yellow and green to blue. The expected range for normal urine specimens from newborns is pH 5-7.<sup>9</sup> The expected range for other normal urine specimens is pH 4.5-8, with an average result of pH 6.<sup>9</sup>

**Protein:** This reaction is based on the phenomenon known as the "protein error" of pH indicators where an indicator that is highly buffered will change color in the presence of proteins (anions) as the indicator releases hydrogen ions to the protein. At a constant pH, the development of any green color is due to the presence of protein. Colors range from yellow to yellow-green for negative results and green to green-blue for positive results. 1-14 mg/dL of protein may be excreted by a normal kidney.<sup>10</sup> A color matching any block greater than trace indicates significant proteinuria. Clinical judgment is required to evaluate the significance of trace results.

**Urobilinogen:** This test is based on a modified Ehrlich reaction between p-diethylaminobenzaldehyde and urobilinogen in strongly acidic medium to produce a pink color. Urobilinogen is one of the major compounds produced in heme synthesis and is a normal substance in urine. The expected range for normal urine with this test is 0.2-1.0 mg/dL (3.5-17 µmol/L).<sup>8</sup> A result of 2.0 mg/dL (35 µmol/L) may be of clinical significance, and the patient specimen should be further evaluated.

**Nitrite:** This test depends upon the conversion of nitrate to nitrite by the action of Gram negative bacteria in the urine. In an acidic medium, nitrite in the urine reacts with p-arsanilic acid to form a diazonium compound. The diazonium compound in turn couples with 1 N-(1-naphthyl) ethylenediamine to produce a pink color. Nitrite is not detectable in normal urine.<sup>9</sup> The nitrite area will be positive in some cases of infection, depending on how long the urine specimens were retained in the bladder prior to collection. Retrieval of positive cases with the nitrite test ranges from as low as 40% in cases where little bladder incubation occurred, to as high as approximately 80% in cases where bladder incubation took place for at least 4 hours.

**Leukocytes:** This test reveals the presence of granulocyte esterases. The esterases cleave a derivatized pyrazole amino acid ester to liberate derivatized hydroxy pyrazole. This pyrazole then reacts with a diazonium salt to produce a beige-pink to purple color. Normal urine specimens generally yield negative results. Trace results may be of questionable clinical significance. When trace results occur, it is recommended to retest using a fresh specimen from the same patient. Repeated trace and positive results are of clinical significance.

### REAGENTS AND PERFORMANCE CHARACTERISTICS

Based on the dry weight at the time of impregnation, the concentrations given may vary within manufacturing tolerances. The following table below indicates read times and performance characteristics for each parameter.

Reagent	Read Time	Composition	Description
Ascorbic Acid (ASC)	30 seconds	2,6-dichlorophenolindophenol; buffer and non-reactive ingredients	Detects ascorbic acid as low as 5-10 mg/dL (0.28-0.56 mmol/L).
Glucose (GLU)	30 seconds	glucose oxidase; peroxidase; potassium iodide; buffer; non-reactive ingredients	Detects glucose as low as 50-100 mg/dL (2.5-5 mmol/L).
Bilirubin (BIL)	30 seconds	2, 4-dichloroaniline diazonium salt; buffer and non-reactive ingredients	Detects bilirubin as low as 0.4-1.0 mg/dL (6.8-17 µmol/L).
Ketone (KET)	40 seconds	sodium nitroprusside; buffer	Detects acetoacetic acid as low as 2.5-5 mg/dL (0.25-0.5 mmol/L).
Specific Gravity (SG)	45 seconds	bromthymol blue indicator; buffer and non-reactive ingredients; poly (methyl vinyl ether/maleic anhydride); sodium hydroxide	Determines urine specific gravity between 1.000 and 1.030. Results correlate with values obtained by refractive index method within ± 0.005.
Blood (BLO)	60 seconds	3,3',5,5'-tetramethylbenzidine (TMB); diisopropylbenzene dihydroperoxide; buffer and non-reactive ingredients	Detects free hemoglobin as low as 0.018-0.060 mg/dL or 5-10 Ery/µL in urine specimens with ascorbic acid content of < 50 mg/dL.
pH	60 seconds	methyl red sodium salt; bromthymol blue; non-reactive ingredients	Permits the quantitative differentiation of pH values within the range of 5-9.
Protein (PRO)	60 seconds	tetrabromophenol blue; buffer and non-reactive ingredients	Detects albumin as low as 7.5-15 mg/dL (0.075-0.15 g/L).
Urobilinogen (URO)	60 seconds	p-diethylaminobenzaldehyde; buffer and non-reactive ingredients	Detects urobilinogen as low as 0.2-1.0 mg/dL (3.5-17 µmol/L).
Nitrite (NIT)	60 seconds	p-arsanilic acid; N-(1-naphthyl) ethylenediamine; non-reactive ingredients	Detects sodium nitrite as low as 0.05-0.1 mg/dL in urine with a low specific gravity and less than 30 mg/dL ascorbic acid.
Leukocytes (LEU)	120 seconds	derivatized pyrrole amino acid ester; diazonium salt; buffer; non-reactive ingredients	Detects leukocytes as low as 9-15 white blood cells Leu/µL in clinical urine.

The performance characteristics of the Urinalysis Reagent Strips (Urine) have been determined in both laboratory and clinical tests. Parameters of importance to the user are sensitivity, specificity, accuracy and precision. Generally, this test has been developed to be specific for the parameters to be measured with the exceptions of the interferences listed. Please refer to the Limitations section in this package insert.

Interpretation of visual results is dependent on several factors: the variability of color perception, the presence or absence of inhibitory factors, and the lighting conditions when the strip is read. Each color block on the chart corresponds to a range of analyte concentrations.

### PRECAUTIONS

- For *in vitro* diagnostic use only. Do not use after the expiration date.
- The strip should remain in the closed canister until use.
- Do not touch the reagent areas of the strip.
- Discard any discolored strips that may have deteriorated.
- All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.
- The used strip should be discarded according to local regulations after testing.

### STORAGE AND STABILITY

Store as packaged in the closed canister either at room temperature or refrigerated (2-30°C). Keep out of direct sunlight. The strip is stable through the expiration date printed on the canister label. Do not remove the desiccant. Remove only enough strips for immediate use. Replace cap immediately and tightly. **DO NOT FREEZE.** Do not use beyond the expiration date.

Note: Once the canister has been opened, the remaining strips are stable for up to 3 months. Stability may be reduced in high humidity conditions.

### SPECIMEN COLLECTION AND PREPARATION

A urine specimen must be collected in a clean and dry container and tested as soon as possible. Do not centrifuge. The use of urine preservatives is not recommended. If testing cannot be done within an hour after voiding, refrigerate the specimen immediately and let it return to room temperature before testing.

Prolonged storage of unpreserved urine at room temperature may result in microbial proliferation with resultant changes in pH. A shift to alkaline pH may cause false positive results with the protein test area. Urine containing glucose may decrease in pH as organisms metabolize the glucose.

Contamination of the urine specimen with skin cleansers containing chlorhexidine may affect protein (and to a lesser extent, specific gravity and bilirubin) test results.

### MATERIALS

#### Materials Provided

- Strips
- Package insert

#### Materials Required But Not Provided


- Specimen collection container
- Timer

### DIRECTIONS FOR USE

Allow the strip, urine specimen, and/or controls to reach room temperature (15-30°C) prior to testing.

- Remove the strip from the closed canister and use it as soon as possible. Immediately close the canister tightly after removing the required number of strip(s). Completely immerse the reagent areas of the strip in fresh, well-mixed urine and immediately remove the strip to avoid dissolving the reagents. See illustration 1 below.
- While removing the strip from the urine, run the edge of the strip against the rim of the urine container to remove excess urine. Hold the strip in a horizontal position and bring the edge of the strip into contact with an absorbent material (e.g. a paper towel) to avoid mixing chemicals from adjacent reagent areas and/or soiling hands with urine. See illustration 2 below.
- Compare the reagent areas to the corresponding color blocks on the canister label at the specified times. Hold the strip close to the color blocks and match carefully. See illustration 3 below.

Note: Results may be read up to 2 minutes after the specified times.



### INTERPRETATION OF RESULTS

Results are obtained by direct comparison of the color blocks printed on the canister label. The color blocks represent nominal values; actual values will vary close to the nominal values. In the event of unexpected or questionable results, the following steps are recommended: confirm that the strips have been tested within the expiration date printed on the canister label, compare results with known positive and negative controls and repeat the test using a new strip. If the problem persists, discontinue using the strip immediately and contact your local distributor.

### QUALITY CONTROL

For best results, performance of reagent strips should be confirmed by testing known positive and negative specimens/controls whenever a new test is performed, or whenever a new canister is first opened. Each laboratory should establish its own goals for adequate standards of performance.

### LIMITATIONS

**Note:** The Urinalysis Reagent Strips (Urine) may be affected by substances that cause abnormal urine color such as drugs containing azo dyes (e.g. Pyridium®. Azo Gantrisin®, Azo Gantanol®), nitrofurantoin (Microdantin®, Furadantin®), and riboflavin.<sup>8</sup> The color development on the test pad may be masked or a color reaction may be produced that could be interpreted as false results.

**Ascorbic acid:** No interference is known.

**Glucose:** The reagent area does not react with lactose, galactose, fructose or other metabolic substances, nor with reducing metabolites of drugs (e.g. salicylates and nalidixic acid). Sensitivity may be decreased in specimens with high specific gravity (>1.025) and with ascorbic acid concentrations of ≥ 25 mg/dL. High ketone levels ≥ 100 mg/dL may cause false negative results for specimens containing a small amount of glucose (50-100 mg/dL).

**Bilirubin:** Bilirubin is absent in normal urine, so any positive result, including a trace positive, indicates an underlying pathological condition and requires further investigation. Reactions may occur with urine containing large doses of chlorpromazine or rifampin that might be mistaken for positive bilirubin.<sup>9</sup> The presence of bilirubin-derived bile pigments may mask the bilirubin reaction. This phenomenon is characterized by color development on the test patch that does not correlate with the colors on the color chart. Large concentrations of ascorbic acid may decrease sensitivity.

**Ketone:** The test does not react with acetone or β-hydroxybutyrate.<sup>8</sup> Urine specimens of high pigment, and other substances containing sulfindryl groups may occasionally give reactions up to and including trace (±).

**Specific Gravity:** Ketoacidosis or protein higher than 300 mg/dL may cause elevated results. Results are not affected by non-ionic urine components such as glucose. If the urine has a pH of 7 or greater, add 0.005 to the specific gravity reading indicated on the color chart.

**Blood:** A uniform blue color indicates the presence of myoglobin, hemoglobin or hemolyzed erythrocytes.<sup>8</sup> Scattered or compacted blue spots indicate intact erythrocytes. To enhance accuracy, separate color scales are provided for hemoglobin and for erythrocytes. Positive results with this test are often seen with urine from menstruating females. It has been reported that urine of high pH reduces sensitivity, while moderate to

high concentration of ascorbic acid may inhibit color formation. Microbial peroxidase, associated with urinary tract infection, may cause a false positive reaction. The test is slightly more sensitive to free hemoglobin and myoglobin than to intact erythrocytes.

**pH:** If the procedure is not followed and excess urine remains on the strip, a phenomenon known as "runover" may occur, in which the acid buffer from the protein reagent will run onto the pH area, causing the pH result to appear artificially low. pH readings are not affected by variations in urinary buffer concentration.

**Protein:** Any green color indicates the presence of protein in the urine. This test is highly sensitive for albumin, and less sensitive to hemoglobin, globulin and mucoprotein.<sup>8</sup> A negative result does not rule out the presence of these other proteins. False positive results may be obtained with highly buffered or alkaline urine. Contamination of urine specimens with quaternary ammonium compounds or skin cleansers containing chlorhexidine may produce false positive results.<sup>8</sup> The urine specimens with high specific gravity may give false negative results.

**Urobilinogen:** All results lower than 1 mg/dL urobilinogen should be interpreted as normal. A negative result does not at any time preclude the absence of urobilinogen. The reagent area may react with interfering substances known to react with Ehrlich's reagent, such as p-aminosalicylic acid and sulfonamides.<sup>9</sup> False negative results may be obtained if formalin is present. The test cannot be used to detect porphobilinogen.

**Nitrite:** The test is specific for nitrite and will not react with any other substance normally excreted in urine. Any degree of uniform pink to red color should be interpreted as a positive result, suggesting the presence of nitrite. Color intensity is not proportional to the number of bacteria present in the urine specimen. Pink spots or pink edges should not be interpreted as a positive result. Comparing the reacted reagent area on a white background may aid in the detection of low nitrite levels, which might otherwise be missed. Ascorbic acid above 30 mg/dL may cause false negatives in urine containing less than 0.05 mg/dL nitrite ions. The sensitivity of this test is reduced for urine specimens with highly buffered alkaline urine or with high specific gravity. A negative result does not at any time preclude the possibility of bacteruria. Negative results may occur in urinary tract infections from organisms that do not contain reductase to convert nitrate to nitrite; when urine has not been retained in the bladder for a sufficient length of time (at least 4 hours) for reduction of nitrate to nitrite to occur; when receiving antibiotic therapy or when dietary nitrate is absent.

**Leukocytes:** The result should be read between 60-120 seconds to allow for complete color development. The intensity of the color that develops is proportional to the number of leukocytes present in the urine specimen. High specific gravity or elevated glucose concentrations (≥ 2,000 mg/dL) may cause test results to be artificially low. The presence of cephalixin, cephalothin, or high concentrations of oxalic acid may also cause test results to be artificially low. Tetracycline may cause decreased reactivity, and high levels of the drug may cause a false negative reaction. High urinary protein may diminish the intensity of the reaction color. This test will not react with erythrocytes or bacteria common in urine.<sup>8</sup>

### BIBLIOGRAPHY

- Free AH, Free HM. *Urinalysis, Critical Discipline of Clinical Science*. CRC Crit. Rev. Clin. Lab. Sci. 3(4): 481-531, 1972.
- Yoder J, Adams EC, Free, AH. *Simultaneous Screening for Urinary Occult Blood, Protein, Glucose, and pH*. Amer. J. Med Tech. 31:285, 1965.
- Shchersten B, Fritz H. *Subnormal Levels of Glucose in Urine*. JAMA 201:129-132, 1967.
- McGarry JD, Lilly. Lecture, 1978: New Perspectives in the Regulation of Ketogenesis. Diabetes 28: 517-523 May, 1978.
- Williamson DH. *Physiological Ketoses, or Why Ketone Bodies?* Postgrad. Med. J. (June Suppl.): 372-375, 1971.
- Paterson P, et al. *Maternal and Fetal Ketone Concentrations in Plasma and Urine*. Lancet: 862-865; April 22, 1967.
- Fraser J, et al. *Studies with a Simplified Nitroprusside Test for Ketone Bodies in Urine, Serum, Plasma and Milk*. Clin. Chem. Acta II: 372-378, 1965.
- Henry JB, et al. Clinical Diagnosis and Management by Laboratory Methods, 20<sup>th</sup> Ed. Philadelphia. Saunders. 371-372, 375, 379, 382, 385, 2001.
- Tietz NW. Clinical Guide to Laboratory Tests. W.B. Saunders Company. 1976.
- Burtis CA, Ashwood ER. Tietz Textbook of Clinical Chemistry 2<sup>nd</sup> Ed. 2205, 1994.

Index of Symbols			
	Consult instructions for use		Tests per kit
	For <i>in vitro</i> diagnostic use only		Use by
	Store between 2-30°C		Lot Number
	Authorized Representative		Manufacturer
			Do not reuse
			Catalog #

 **ACON Laboratories, Inc.**  
10125 Mesa Rim Road,  
San Diego, CA 92121, USA

 **MDSS GmbH**  
Schiffgraben 41  
30175 Hannover, Germany



浙江东方基因生物制品股份有限公司  
Zhejiang Orient Gene Biotech Co.,LTD

---

## STATEMENT

We, Zhejiang Orient Gene Biotech Co., Ltd , having a registered office at 3787#, East Yangguang Avenue, Dipu Street Anji 313300, Huzhou, Zhejiang, China assign SRL SANMEDICO having a registered office at A. Corobceanu street 7A, apt. 9, Chişinău MD-2012, Moldova, as non-exclusive authorized representative for Orient Gene Brand product in correspondence with the conditions of directive 98/79/EEC.


We declare that the company mentioned above is authorized to register, notify, renew or modify the registration of medical devices on the territory of the Republic of Moldova.

This Statement letter will be valid from Mar.22th,2024 to Mar.21th, 2025.

Zhejiang Orient Gene Biotech Co.,Ltd

General Manager:

Date:2024/3/22



---

地址：浙江省湖州市安吉县递铺镇阳光大道东段 3787 号  
Add: 3787#, East Yangguang Avenue, Dipu Street Anji 313300, Huzhou, Zhejiang, China  
电话 Tel:+86-572-5226111 传真 Fax: +86-572-5226222 邮编 P.C.:313300



# Certificate

No. Q5 092305 0001 Rev. 02

**Holder of Certificate:** **Zhejiang Orient Gene Biotech Co., Ltd.**  
3787#, East Yangguang Avenue, Dipu Street Anji  
313300 Huzhou, Zhejiang  
PEOPLE'S REPUBLIC OF CHINA

**Certification Mark:**



**Scope of Certificate:** **Design and Development, Production and Distribution of In Vitro Diagnostic Reagent and Instrument for the Detection of Drugs of Abuse, Fertility, Infectious Diseases, Oncology, Biochemistry, Cardiac Diseases, Allergic Disease based on Rapid Test, PCR and Liquid Biochip Method.**

The Certification Body of TÜV SÜD Product Service GmbH certifies that the company mentioned above has established and is maintaining a quality management system, which meets the requirements of the listed standard(s). All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: [www.tuvsud.com/ps-cert?q=cert:Q5 092305 0001 Rev. 02](http://www.tuvsud.com/ps-cert?q=cert:Q5 092305 0001 Rev. 02)

**Report No.:** SH2398804

**Valid from:** 2024-03-17

**Valid until:** 2027-03-16

**Date,** 2024-03-01

Christoph Dicks  
Head of Certification/Notified Body



# Certificate

No. Q5 092305 0001 Rev. 02

**Applied Standard(s):** ISO 13485:2016  
(EN ISO 13485:2016/AC:2018, EN ISO 13485:2016/A11:2021)  
Medical devices - Quality management systems -  
Requirements for regulatory purposes

**Facility(ies):** **Zhejiang Orient Gene Biotech Co., Ltd.**  
3787#, East Yangguang Avenue, Dipu Street Anji, 313300  
Huzhou, Zhejiang, PEOPLE'S REPUBLIC OF CHINA

See Scope of Certificate



Benannt durch/Designated by  
Zentralstelle der Länder  
für Gesundheitsschutz  
bei Arzneimitteln und  
Medizinprodukten  
www.zlg.de  
ZLG-BS-245.10.07



Product Service

# EC Certificate

EC Design-Examination Certificate

Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex IV (4) (List A)

**No. V7 092378 0009 Rev. 00**

**Manufacturer:**

**Healgen Scientific Limited  
Liability Company**

3818 Fuqua Street  
Houston TX 77047  
USA

**Product:**

**Screening test for Hepatitis C marker**

The Certification Body of TÜV SÜD Product Service GmbH declares that a design examination has been carried out on the respective devices in accordance with IVDD Annex IV (4). The design of the devices conforms to the requirements of this Directive. All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: [www.tuvsud.com/ps-cert?q=cert:V7 092378 0009 Rev. 00](http://www.tuvsud.com/ps-cert?q=cert:V7 092378 0009 Rev. 00)

**Report No.:**

713234651

**Valid from:**

2022-04-22

**Valid until:**

2025-05-26

**Date,**

2022-04-22

Christoph Dicks  
Head of Certification/Notified Body



# EC Certificate

EC Design-Examination Certificate

Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex IV (4) (List A)

**No. V7 092378 0009 Rev. 00**

**Model(s):**

**HCV Hepatitis C Virus Rapid Test**

**Facility(ies):**

Zhejiang Orient Gene Biotech Co., Ltd.  
3787#, East Yangguang Avenue, Dipu Street Anji,  
313300 Huzhou, Zhejiang, PEOPLE'S REPUBLIC OF CHINA

**Parameters:**

Model Name:

Model No.:

--

HCV Hepatitis C Virus Rapid Test  
(Serum / Plasma) (Cassette)

GCHCV-302a

HCV Hepatitis C Virus Rapid Test  
(Whole Blood /Serum / Plasma) (Cassette)

GCHCV-402a



# EC Declaration of Conformity

In accordance with Directive 98/79/EC

**Legal Manufacturer:** Healgen Scientific Limited Liability Company

**Legal Manufacturer Address:** 3818 Fuqua Street, Houston, TX 77047, USA.

Declares, that the products  
Product Name and Model(s)

Orient Gene HCV Hepatitis C Virus Rapid Test (Serum/Plasma) (Cassette)	GCHCV-302a
Orient Gene HCV Hepatitis C Virus Rapid Test (Whole blood/Serum/Plasma)(Cassette)	GCHCV-402a

EDMA Code: 15 70 02 02

**Classification:** Annex II List A  
**Conformity assessment route:** Annex IV (Full Quality Assurance)

Compliance of the designated product with the Directive 98/79/EC has been assessed and certified by the Notified Body

**Notified Body:** TÜV SÜD Product Service GmbH

**Notified Body Address:** Munich Branch Ridlerstraße 65 80339 München Germany

**EC Certificate No.:** V1 092378 0004 Rev. 02 Valid until: 2025-05-26

**EC Design-Examination Certificate No.:** V7 092378 0009 Rev. 00 Valid until: 2025-05-26

It bears the mark

**CE 0123**

We, the Manufacturer, herewith declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In-Vitro Diagnostic Medical Devices.

We hereby explicitly appoint

**EC Representative Name:** QARAD b.v.b.a.

**EC Representative Address:** Cipalstraat 3, B-2440 Geel, Belgium

to act as our European Authorized Representative as defined in the aforementioned Directive.

I, the undersigned, hereby declare that the medical devices specified above conform with the directive 98/79/EC on in vitro diagnostic medical devices and pertinent essential requirements

Signature: 

Name of authorized signatory: Joyce Pang

Position held in the company: Vice-President

Date: 2022.4.22



浙江东方基因生物制品股份有限公司  
Zhejiang Orient Gene Biotech Co., LTD



CE-DOC-OG038  
Version 2.0

# EC Declaration of Conformity

In accordance with Directive 98/79/EC

**Legal Manufacturer:** *Zhejiang Orient Gene Biotech Co., Ltd*

**Legal Manufacturer Address:** *3787#, East Yangguang Avenue, Dipu Street,  
Anji 313300, Huzhou, Zhejiang, China*

Declares, that the products  
Product Name and Model(s)

Troponin I Rapid Test Cassette (Whole Blood/Serum/Plasma)	GDTRO-402a
Troponin I Rapid Test Cassette (Whole Blood/Serum/Plasma)	GDTRO-402b

Classification: *Other*  
Conformity assessment route: *Annex III (EC DECLARATION OF CONFORMITY)*

We, the Manufacturer, herewith declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In-Vitro Diagnostic Medical Devices.

We hereby explicitly appoint

**EC Representative's Name:** *Shanghai International Holding Corp. GmbH (Europe)*

**EC Representative's Address:** *Eiffestrasse 80, 20537 Hamburg, Germany*

to act as our European Authorized Representative as defined in the aforementioned Directive.

I, the undersigned, hereby declare that the medical devices specified above conform with the directive 98/79/EC on in vitro diagnostic medical devices and pertinent essential requirements

Date Signed: August 11, 2020

Name of authorized signatory: *Joyce Pang*  
Position held in the company: *Vice-President*



浙江东方基因生物制品股份有限公司  
Zhejiang Orient Gene Biotech Co., LTD



CE-DOC-OG048  
Version 3.0

# EC Declaration of Conformity

In accordance with Directive 98/79/EC

**Legal Manufacturer:** *Zhejiang Orient Gene Biotech Co., Ltd*

**Legal Manufacturer Address:** *3787#, East Yangguang Avenue, Dipu Street,  
Anji 313300, Huzhou, Zhejiang, China*

Declares, that the products  
Product Name and Model(s)

D-Dimer Rapid Test Cassette (Whole Blood/Plasma)	GDDDI-402b
--	------------

Classification: Other

Conformity assessment route: *Annex III (EC DECLARATION OF CONFORMITY)*

We, the Manufacturer, herewith declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In-Vitro Diagnostic Medical Devices.

We hereby explicitly appoint

**EC Representative's Name:** QARAD BV

**EC Representative's Address:** Ciplastraat 3, 2440 Geel BELGIUM

to act as our European Authorized Representative as defined in the aforementioned Directive.

I, the undersigned, hereby declare that the medical devices specified above conform with the directive 98/79/EC on in vitro diagnostic medical devices and pertinent essential requirements

Date Signed: November 11, 2021

Name of authorized signatory: Joyce Pang  
Position held in the company: Vice-President





浙江东方基因生物制品股份有限公司  
Zhejiang Orient Gene Biotech Co., LTD



CE-DOC-OG077  
Version 1.0

# EC Declaration of Conformity

In accordance with Directive 98/79/EC

**Legal Manufacturer:** *Zhejiang Orient Gene Biotech Co., Ltd*

**Legal Manufacturer Address:** *3787#, East Yangguang Avenue, Dipu Street,  
Anji 313300, Huzhou, Zhejiang, China*

Declares, that the products  
Product Name and Model(s)

CK-MB Rapid Test Cassette (Whole Blood/Serum/Plasma)	GDCKM-402a
--	------------

Classification: *Other*

Conformity assessment route: *Annex III (EC DECLARATION OF CONFORMITY)*

We, the Manufacturer, herewith declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In-Vitro Diagnostic Medical Devices.

We hereby explicitly appoint

**EC Representative's Name:** *Shanghai International Holding Corp. GmbH (Europe)*

**EC Representative's Address:** *Eiffestrasse 80, 20537 Hamburg, Germany*

to act as our European Authorized Representative as defined in the aforementioned Directive.

I, the undersigned, hereby declare that the medical devices specified above conform with the directive 98/79/EC on in vitro diagnostic medical devices and pertinent essential requirements

Date Signed: April 3, 2018

Name of authorized signatory: *Joyce Pang*  
Position held in the company: *Vice-President*



Zhejiang Orient Gene Biotech Co., LTD

## CERTIFICATE OF ANALYSIS

Product Name: HBsAg Rapid Test (Whole blood/Serum/Plasma) (Cassette)

Catalog NO.: GCHBsg-402a

Purchase NO.: 2023-IEU157#

Lot NO.: 2310203

Quantity: 3000pcs

Expiration Date: 2025.09

CONTROLS		SPECIFICATION	TEST RESULT	CONCLUSION
Negative Specimens		Negative	Negative	<input checked="" type="checkbox"/> Pass <input type="checkbox"/> Fail
Positive Specimens	1ng/ml	Positive	Positive	<input checked="" type="checkbox"/> Pass <input type="checkbox"/> Fail
	2ng/ml	Positive	Positive	<input checked="" type="checkbox"/> Pass <input type="checkbox"/> Fail
	3ng/ml	Positive	Positive	<input checked="" type="checkbox"/> Pass <input type="checkbox"/> Fail
	5ng/ml	Positive	Positive	<input checked="" type="checkbox"/> Pass <input type="checkbox"/> Fail

Conclusion: ☒Pass: All results meet QC standard.  
☐Fail

Test by:

QC Supervisor:

Date:

2023.10.28

# Hepatitis B Surface Antigen Rapid Test Cassette (Whole blood/Serum/Plasma)

## INTENDED USE

The Hepatitis B Surface Antigen Rapid Test Cassette (Whole Blood/Serum/Plasma) is a lateral flow chromatographic immunoassay for the qualitative detection of Hepatitis B surface antigen (HBsAg) in human whole blood, serum or plasma. It is intended to be used as a screening test and as an aid in the diagnosis of infection with Hepatitis B virus (HBV). Any reactive specimen with the HBsAg Rapid Test Cassette must be confirmed with alternative testing method(s) and clinical findings.

## INTRODUCTION

Viral hepatitis is a systemic disease primarily involving the liver. Most cases of acute viral hepatitis are caused by Hepatitis A virus, Hepatitis B virus (HBV) or Hepatitis C virus. The complex antigen found on the surface of HBV is called HBsAg. The presence of HBsAg in serum or plasma is an indication of an active Hepatitis B infection, either acute or chronic. In a typical Hepatitis B infection, HBsAg will be detected 2 to 4 weeks before the ALT level becomes abnormal and 3 to 5 weeks before symptoms or jaundice develop. HBsAg has four principal subtypes: adw, ayw, adr and ayr. Because of antigenic heterogeneity of the determinant, there are 10 major serotypes of Hepatitis B virus. The HBsAg Test Cassette (Whole Blood/Serum/Plasma) is a rapid test to qualitatively detect the presence of HBsAg in whole blood, serum or plasma specimens. The test utilizes a combination of double monoclonal antibodies to selectively detect elevated levels of HBsAg in whole blood, serum or plasma.

## PRINCIPLE

The Hepatitis B Surface Antigen Rapid Test Cassette (Whole Blood/Serum/Plasma) is a lateral flow chromatographic immunoassay based on the principle of the double antibody-sandwich technique. The membrane is pre-coated with anti-HBsAg antibodies on the test line region of the test. During testing, Hepatitis B Surface Antigen in the whole blood, serum or plasma specimen reacts with the particle coated with anti-HBsAg antibody. The mixture migrates upward on the membrane, chromatographically by capillary action to react with anti-HBsAg antibodies on the membrane and generate a colored line. The presence of this colored line in the test region indicates a positive result, while its absence indicates a negative result. To serve as a procedural control, a colored line will always appear in the control line region indicating that the proper volume of specimen has been added and membrane wicking has occurred.

## PRODUCT CONTENTS

The Hepatitis B Surface Antigen Rapid Test Cassette (Whole Blood/Serum/Plasma) containing anti-HBsAg antibodies particles and anti-HBsAg antibodies coated on the membrane.

## MATERIALS SUPPLIED

Test cassette	Dropper	Buffer	Package insert
---------------	---------	--------	----------------

## MATERIAL REQUIRED BUT NOT PROVIDED

1. Specimen collection containers
2. Lancets (for fingerstick whole blood only)
3. Centrifuge (for plasma only)
4. Timer
5. Heparinized capillary tubes and dispensing bulb (for fingerstick whole blood only)

## STORAGE AND STABILITY

The kit can be stored at room temperature or refrigerated (2-30°C). The test device is stable through the expiration date printed on the sealed pouch. The test cassette must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

## WARNINGS AND PRECAUTIONS

1. For professional In Vitro diagnostic use only. Do not use after expiration date.
2. Warning: the reagents in this kit contain sodium azide which may react with lead or copper plumbing to form potentially explosive metal azides. When disposing of such reagents, always flush with large volumes of water to prevent azide build-up.

3. Do not use it if the tube/pouch is damaged or broken.
4. Test is for single use only. Do not re-use under any circumstances.
5. Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout testing and follow the standard procedures for proper disposal of specimens.
6. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are assayed.
7. Humidity and temperature can adversely affect results.
8. Do not perform the test in a room with strong air flow, i.e. electric fan or strong air-conditioning.

## SPECIMEN COLLECTION AND PREPARATION

1. Hepatitis B Surface Antigen Rapid Test Cassette (Whole Blood/Serum/Plasma) can be performed using whole blood (from venipuncture or fingerstick), serum or plasma.
2. To collect Fingerstick Whole Blood specimens:
  - Wash the patient's hand with soap and warm water or clean with an alcohol swab. Allow to dry.
  - Massage the hand without touching the puncture site by rubbing down the hand towards the fingertip of the middle or ring finger.
  - Puncture the skin with a new sterile lancet for each person. Wipe away the first sign of blood.
  - Gently rub the hand from wrist to palm to finger to form a rounded drop of blood over the puncture site.
  - Add the Fingerstick Whole Blood specimen to the test cassette by using a capillary tube:
    - Touch the end of the capillary tube to the blood until filled to approximately 50µL. Avoid air bubbles.
    - Place the bulb onto the top end of the capillary tube, then squeeze the bulb to dispense the whole blood into the specimen well (S) of the test cassette.
  - Add the Fingerstick Whole Blood specimen to the test cassette by using hanging drops:
    - Position the patient's finger so that the drop of blood is just above the specimen well (S) of the test cassette.
    - Allow 2 hanging drops of fingerstick whole blood to fall into the center of specimen well (S) on the test cassette, or move the patient's finger so that the hanging drop touches the center of the specimen well (S). Avoid touching the finger directly to the specimen well (S).
3. Separate serum or plasma from blood as soon as possible to avoid hemolysis. Use only clear, non-hemolyzed specimens.
4. Testing should be performed immediately after specimen collection. Do not leave the specimens at room temperature for prolonged periods. Serum and plasma specimens may be stored at 2-8°C for up to 3 days. For long term storage, specimens should be kept below -20°C. Whole blood collected by venipuncture should be stored at 2-8°C if the test is to be run within 2 days of collection. Do not freeze whole blood specimens. Whole blood collected by fingerstick should be tested immediately.
5. Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Specimens should not be frozen and thawed repeatedly.
6. If specimens are to be shipped, they should be packed in compliance with local regulations covering the transportation of etiologic agents.

## TEST PROCEDURE

**Allow test cassette, specimen, buffer and/or controls to equilibrate to room temperature (15-30°C) prior to testing.**


1. Remove the test cassette from the foil pouch and use it as soon as possible. Best results will be obtained if the assay is performed within one hour.
2. Place the test cassette on a clean and level surface.

**For Serum or Plasma Specimens:** Hold the dropper vertically and transfer 2-3 drops of serum or plasma (approximately 60-90µL) to the specimen well (S) of the test cassette. See illustration below.

**For Venipuncture Whole Blood Specimens:** Hold the dropper vertically and transfer 2 drops of venipuncture whole blood (approximately 50µL) to the specimen well (S) of the test cassette, then add 1 drop of buffer (approximately 40 µL) and start the timer. See illustration below.

**For Fingerstick Whole Blood Specimens:** Allow 2 hanging drops of fingerstick whole blood (approximately 50 µL) to fall into the center of the specimen well (S) on the test cassette, then add 1 drop of buffer (approximately 40 µL) and start the timer. See illustration below.

3. Wait for the red line(s) to appear. The result should be read in 15 minutes. Do not interpret the result after 15 minutes



### INTERPRETATION OF RESULTS



**POSITIVE:** Two distinct red lines appear. One line should be in the control region (C) and another line should be in the test region (T).

**NEGATIVE:** One red line appears in the control region (C). No apparent red or pink line appears in the test region (T).

**INVALID:** Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test Cassette. If the problem persists discontinue using the test kit immediately and contact your local distributor

### QUALITY CONTROL

A procedural control is included in the test. A red line appearing in the control region (C) is the internal procedural control. It confirms sufficient specimen volume and correct procedural technique. Control standards are not supplied with this kit; however, it is recommended that positive and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.

### LIMITATIONS

1. Though the Hepatitis B Surface Antigen Rapid Test Cassette (Whole Blood/Serum/Plasma) is a reliable screening assay, it should not be used as a sole criterion for diagnosis of HBV infection.
2. The HBsAg Rapid Test Cassette is limited to the qualitative detection of HBsAg in human whole blood, serum or plasma. The intensity of the test band does not have linear correlation with HBsAg titer in the specimen.
3. A negative test result does not preclude the possibility of exposure to or infection with HBV. Infection through recent exposure (seroconversion) to HBV may not be detectable.
4. A negative result can occur if the quantity of HBsAg present in the specimen is below the detection limits of the assay (lower than 1 ng/mL), or the HBsAg that are detected are not present during the stage of disease in which a sample is collected.
5. Interference due to heterophile antibodies, Rheumatoid Factors and other nonanalyte substances in patient's serum, capable of binding antibodies multivalently and providing erroneous analyte detection in immunoassays, has been reported in various studies. Both laboratory professionals and clinicians must be vigilant to this possibility of antibody interference. Results that appear to be internally inconsistent or incompatible with the clinical presentation should invoke suspicion of the presence of an endogenous artifact and lead to appropriate in vitro investigative action.
6. This kit is intended ONLY for testing of individual samples. Do not use it for testing of cadaver samples, saliva, urine or other body fluids, or pooled (mixed) blood.
7. As with all diagnostic tests, a definitive clinical diagnosis should not be based on the result of a single test, but should only be made by the physician after all clinical and laboratory findings have been evaluated.

### PERFORMANCE CHARACTERISTICS

#### Sensitivity:

The Hepatitis B Surface Antigen Rapid Test Cassette (Whole Blood/Serum/Plasma) has been tested with a sensitivity panel ranging from 0 to 300 ng/mL. All 10 HBsAg subtypes produced positive results on the Hepatitis B Surface Antigen Rapid Test Cassette (Whole Blood/Serum/Plasma). The test can detect 5ng/mL of HBsAg in 10 minutes, and 1 ng/mL of HBsAg in 15 minutes.

#### Specificity:

Antibodies used for the Hepatitis B Surface Antigen Rapid Test Cassette (Whole Blood/Serum/Plasma) were developed against whole Hepatitis B antigen isolated from Hepatitis B virus. Specificity of the Hepatitis B Surface Antigen Rapid Test Cassette (Whole Blood/Serum/Plasma) was also tested with laboratory strains of Hepatitis A and Hepatitis C. They all yielded negative results.

#### Hepatitis B Surface Antigen Rapid Test Cassette (Whole Blood/Serum/Plasma) vs. EIA test

Method	EIA		Total Results
	Results	Positive	Negative
Hepatitis B Surface Antigen Rapid Test Cassette (Whole Blood/Serum/Plasma)	Positive	345	5
	Negative	2	980
Total Results		347	985
			1332

Relative sensitivity: 99.4%

Relative specificity 99.5%

Accuracy: 99.5%

### REFERENCE

1. Blumberg, B. S. The Discovery of Australian Antigen and its relation to viral hepatitis. Vitro. 1971; 7: 223

Catalogue No:GCHBsg-402a

Effective Date: 2023-08-22

B20137-05

# CK-MB Rapid Test Cassette (Whole Blood/Serum/Plasma)



A rapid test for the qualitative detection of CK-MB in whole blood, serum or plasma.  
For professional *in vitro* diagnostic use only.

## INTENDED USE

The CK-MB Rapid Test Cassette (Whole Blood/Serum/Plasma) is a rapid chromatographic immunoassay for the qualitative detection of human CK-MB in whole blood, serum or plasma as an aid in the diagnosis of myocardial infarction (MI).

## SUMMARY

Creatine Kinase MB (CK-MB) is an enzyme present in the cardiac muscle with a molecular weight of 87.0 kDa. Creatine Kinase is a dimeric molecule formed from two subunits designated as "M" and "B" which combine to form three<sup>1</sup> different isoenzymes, CK-MM, CKBB, and CK-MB. CK-MB is the isoenzyme of Creatine Kinase most involved in the metabolism of cardiac muscle tissue.<sup>2</sup> The release of CK-MB into the blood following MI can be detected within 3-8 hours after the onset of symptoms. It peaks within 9 to 30 hours, and returns to baseline levels within 48 to 72 hours.<sup>3</sup> CK-MB is one of the most important cardiac markers and is widely recognized as the traditional marker for the diagnosis of MI. The CK-MB Rapid Test Cassette (Whole Blood/Serum/Plasma) is a simple test that utilizes a combination of anti-CK-MB antibody coated particles and capture reagent to detect CK-MB in whole blood, serum or plasma. The minimum detection level is 5 ng/mL.

## PRINCIPLE

The CK-MB Rapid Test Cassette (Whole Blood/Serum/Plasma) is a qualitative, membrane based immunoassay for the detection of CK-MB in whole blood, serum or plasma. The membrane is pre-coated with capture reagent on the test line region of the test. During testing, the whole blood, serum or plasma specimen reacts with the particle coated with anti-CK-MB antibodies. The mixture migrates upward on the membrane chromatographically by capillary action to react with capture reagent on the membrane and generate a colored line. The presence of this colored line in the test line region indicates a positive result, while its absence indicates a negative result. To serve as a procedural control, a colored line will always appear in the control line region indicating that proper volume of specimen has been added and membrane wicking has occurred.

## REAGENTS

The test contains anti-CK-MB antibody coated particles and capture reagent coated on the membrane.

## PRECAUTIONS

- For professional *in vitro* diagnostic use only. Do not use after expiration date.
- The test must remain in the sealed pouch until use.
- Do not eat, drink or smoke in the area where the specimens or kits are handled.
- Do not use if pouch is damaged.
- Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout the procedure and follow the standard procedures for proper disposal of specimens.
- Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are being tested.
- Humidity and temperature can adversely affect results.
- The used test should be discarded according to local regulations.

## STORAGE AND STABILITY

Store as packaged in the sealed pouch either at room temperature or refrigerated (2-30°C). The test is stable through the expiration date printed on the sealed pouch. The test must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

## SPECIMEN COLLECTION AND PREPARATION

- The CK-MB Rapid Test Cassette (Whole Blood/Serum/Plasma) can be performed using whole blood (from venipuncture or fingerstick), serum or plasma.
- To collect Fingerstick Whole Blood specimens:
  - Wash the patient's hand with soap and warm water or clean with an alcohol swab. Allow to dry.
  - Massage the hand without touching the puncture site by rubbing down the hand towards the fingertip of the middle or ring finger.
  - Puncture the skin with a sterile lancet. Wipe away the first sign of blood.
  - Gently rub the hand from wrist to palm to finger to form a rounded drop of blood over the puncture site.
  - Position the patient's finger so that the drop of blood is just above the specimen well (S) of the test device.
  - Allow 2 hanging drops of fingerstick whole blood to fall into the specimen well (S) of the test device, or move the patient's finger so that the hanging drop touches the specimen well (S). Avoid touching the finger directly to the specimen well (S).
- Separate serum or plasma from blood as soon as possible to avoid hemolysis. Use only clear, non-hemolyzed specimens.
- Testing should be performed immediately after specimen collection. Do not leave the specimens at room temperature for prolonged periods. Serum and plasma specimens may be stored at 2-8°C for up to 3 days. For long-term storage, specimens should be kept below -20°C. Whole blood collected by venipuncture should be stored at 2-8°C if the test is to be run within 2 days of

collection. Do not freeze whole blood specimens. Whole blood collected by fingerstick should be tested immediately.

- Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Specimens should not be frozen and thawed repeatedly.
- If specimens are to be shipped, they should be packed in compliance with local regulations covering the transportation of etiologic agents.

## MATERIALS

Materials Provided

25 Sealed pouches each containing a test cassette, a dropper and a desiccant

1 Buffer, 4.0 mL

1 Package insert

Materials Required But Not Provided

- Specimen collection containers
- Lancets (for fingerstick whole blood only)
- Centrifuge
- Timer

## DIRECTIONS FOR USE

Allow the test, specimen and/or controls to reach room temperature (15-30°C) prior to testing.



1. Bring the pouch to room temperature before opening it. Remove the test device from the sealed pouch and use it as soon as possible. Best results will be obtained if the test is performed immediately after opening the foil pouch.
2. Place the test device on a clean and level surface.

For Serum or Plasma specimens: Hold the dropper vertically and transfer 2 drops of serum or plasma (approximately 50 µL) to the specimen well (S) of the test device, then start the timer. See illustration below.

For Venipuncture Whole Blood specimens: Hold the dropper vertically and transfer 2 drops of venipuncture whole blood (approximately 50 µL) to the specimen well (S) of the test device, then add 1 drop of buffer (approximately 40 µL) and start the timer. See illustration below.

For Fingerstick Whole Blood specimens: Allow 2 hanging drops of fingerstick whole blood specimen (approximately 50 µL) to fall into the center of the specimen well (S) on the test device, then add 1 drop of buffer (approximately 40 µL) and start the timer. See illustration below.

3. Wait for the colored line(s) to appear. Read results at 10 minutes. Do not interpret results after 20 minutes.



## INTERPRETATION OF RESULTS

(Please refer to the illustration above)

**POSITIVE:** Two distinct colored lines appear. One colored line should be in the control line region (C) and another apparent colored line should be in the test line region (T).

**NEGATIVE:** One colored line appears in the control line region (C). No line appears in the test line region (T).

**INVALID:** Control line (C) fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

## QUALITY CONTROL

An internal procedural control is included in the test. A colored line appearing in the control line region (C) is an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique. Control standards are not supplied with this kit; however it is recommended that positive and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.

## LIMITATIONS

1. The CK-MB Rapid Test Cassette (Whole Blood/Serum/Plasma) is for *in vitro* diagnostic use only. This test should be used for the detection of CK-MB in whole blood, serum or plasma specimens only. Neither the quantitative value nor the rate of increase in CK-MB can be determined by this qualitative test.
2. The CK-MB Rapid Test Cassette (Whole Blood/Serum/Plasma) will only indicate the qualitative level of CK-MB in the specimen and should not be used as the sole criteria for the diagnosis of myocardial infarction.
3. The CK-MB Rapid Test Cassette (Whole Blood/Serum/Plasma) can detect no less than 5 ng/mL of CK-MB in specimens. A negative result at any time does not preclude the possibility of myocardial infarction.
4. As with all diagnostic tests, all results must be interpreted together with other clinical information available to the physician.
5. Unusually high titers of heterophile antibodies or rheumatoid factor (RF) may affect results. Even if the test results are positive, further clinical evaluation should be considered with other clinical information available to the physician.
6. There is a slight possibility that some whole blood specimens with very high viscosity or which have been stored for more than 2 days may not run properly on the test device. Repeat the test with a serum or plasma specimen from the same patient using a new test device.

## EXPECTED VALUES

The CK-MB Rapid Test Cassette (Whole Blood/Serum/Plasma) has been compared with a leading commercial CK-MB EIA test, demonstrating an overall accuracy of 99.8%.

## PERFORMANCE CHARACTERISTICS

### Sensitivity and Specificity

The CK-MB Rapid Test Cassette (Whole Blood/Serum/Plasma) has been evaluated with a leading commercial CK-MB EIA test using clinical specimens. The results show that the sensitivity of the CK-MB Rapid Test Cassette (Whole Blood/Serum/Plasma) is 100% and the specificity is 99.8% relative to the leading EIA test.

### CK-MB Rapid Test vs. EIA

Method		EIA		Total Results
CK-MB	Results	Positive	Negative	
	Positive	54	1	55
	Negative	0	422	422
Total Results		54	423	477

Relative Sensitivity: 100% (93.4%-100.0%) \*

Relative Specificity: 99.8% (98.7%-99.9%)\*

Accuracy: 99.8% (98.8%-99.9%)\* \* 95% Confidence Interval

## PRECISION

### Intra-Assay

Within-run precision has been determined by using replicates of 10 tests for each of three lots using CK-MB specimen levels at 0 ng/mL, 5 ng/mL, 10 ng/mL, 20 ng/mL and 40 ng/mL. The specimens were correctly identified >99% of the time.

### Inter-Assay

Between-run precision has been determined by 3 independent assays on the same five specimens: 0 ng/mL, 5 ng/mL, 10 ng/mL, 20 ng/mL and 40 ng/mL of CK-MB. Three different lots of the CK-MB Rapid Test Cassette (Whole Blood/Serum /Plasma) have been tested using these specimens. The specimens were correctly identified >99% of the time.

### Cross-Reactivity

Sera containing known amounts of 1,390 ng/mL CK-MM and 1,000 ng/mL CK-BB have been tested . No cross-reactivity was observed, indicating that the CK-MB Rapid Test Cassette (Whole Blood/Serum/Plasma) has a high degree of specificity for CK-MB.

### Interfering Substances

The CK-MB Rapid Test Cassette (Whole Blood/Serum/Plasma) has been tested and no interference was observed in specimens containing 110 mg/mL human albumin, 6 mg/mL bilirubin, 10 mg/mL hemoglobin, 5 mg/mL cholesterol and 15 mg/mL triglycerides.


## BIBLIOGRAPHY


1. Apple FS, Preese LM. Creatine kinase-MB: detection of myocardial infarction and monitoring reperfusion. J Clin Immunoassay, 17:24-9, 1994.
2. Lee, T.H., Goldman, L. Serum enzyme assays in the diagnosis of acute myocardial infarction. Ann Intern Med, 105:221-233, 1986.

3. Kallner A, Sylven C, Brodin. U, et al. Early diagnosis of acute myocardial infarction; a comparison between chemical predictors. Scand J Clin Lab Invest, 49:633-9, 1989.

## INDEX OF SYMBOLS

	Consult instructions for use		Tests per kit		Authorized Representative
	For <i>in vitro</i> diagnostic use only		Use by		Do not reuse
	Store between 2~30°C		Lot Number		Catalog#

 Zhejiang Orient Gene Biotech Co.,Ltd  
Address: 3787#, East Yangguang Avenue, Dipu Street,  
Anji 313300, Huzhou, Zhejiang, China  
Tel: +86-572-5226111 Fax: +86-572-5226222  
Website: www.orientgene.com

 Shanghai International Holding Corp. GmbH (Europe)  
Add: Eiffestrasse 80, 20537 Hamburg, Germany

 GDCKM-402a



# D-Dimer Rapid Test Cassette (Whole Blood/Plasma)

## INTENDED USE

The D-Dimer Rapid Test Cassette (Whole Blood/Plasma) is a rapid chromatographic immunoassay for the qualitative detection of D-dimer in human whole blood or plasma. It is intended to be used as a screening test and as an aid in the diagnosis of disseminated intravascular coagulation (DIC), deep vein thrombosis (DVT). Any reactive specimen with the D-Dimer Rapid Test Cassette (Whole Blood/Plasma) must be confirmed with alternative testing method(s) and clinical findings.

## INTRODUCTION

During blood coagulation process, fibrinogen is converted to fibrin by the activation of thrombin. The resulting fibrin monomers polymerise to form a soluble gel of non-cross-linked fibrin. This fibrin gel is then converted to cross-linked fibrin by thrombin activated Factor XIII to form an insoluble fibrin clot. Production of plasmin, the major clot-lysing enzyme, is triggered when a fibrin clot is formed. Although fibrinogen and fibrin are both cleaved by the fibrinolytic enzyme plasmin to yield degradation products, only degradation products from cross-linked fibrin contain D-dimer and are called cross-linked fibrin degradation products. Therefore, fibrin derivatives in human blood or plasma containing D-dimer are a specific marker of fibrinolysis.

The D-Dimer Rapid Test Cassette (Whole Blood/Plasma) is a rapid test that qualitative detects the presence of D-dimer in whole blood or plasma specimens at the sensitivity of 500 ng/mL. The test utilizes a combination of monoclonal antibodies to selectively detect elevated levels of D-dimer in whole blood or plasma. At the level of claimed sensitivity, the D-Dimer Rapid Test Cassette (Whole Blood/Plasma) shows no cross-reactivity interference from the related Troponin I, Troponin T, CK-MB, Myoglobin or others at high physiological levels.

## PRINCIPLE

The D-Dimer Rapid Test Cassette (Whole Blood/Plasma) is immunochromatographic assay including D-Dimer specific monoclonal antibody conjugated to colloidal gold particles, second D-Dimer specific monoclonal antibody on test line and Goat anti-mouse IgG antibody on the control line. When the specimen containing D-Dimer is added to sample pad, it moves to conjugate pad and forms a complex (D-Dimer and antibody-gold conjugate). The complex migrates through a nitrocellulose membrane by capillary action and captured at test line which is second D-Dimer specific monoclonal antibody has been bound. The complex is concentrated at test line and a pink or purple line is showed if the D-Dimer concentration is higher than the clinically established cut-off. Uncaptured gold conjugate continues to flow towards control line which Goat anti-mouse IgG is bound and forms a pink or purple color line, indicating test is working as designed and the result is valid. If the control line does not appear, the test result is not valid.

## PRODUCT CONTENTS

The D-Dimer Rapid Test Cassette (Whole Blood/Plasma) containing Anti-D-dimer particles and Anti-D-dimer coated on the membrane.

## MATERIALS SUPPLIED

25 Sealed pouches each containing a test cassette, a pipette dropper and a desiccant  
1 Buffer, 4.0 mL  
1 Package insert

## MATERIAL REQUIRED BUT NOT PROVIDED

Timer                      Lancing device for whole blood test

## STORAGE AND STABILITY

The kit can be stored at room temperature or refrigerated (2-30°C). The test Cassette is stable through the expiration date printed on the sealed pouch. The test Cassette must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

## WARNINGS AND PRECAUTIONS

- For professional *in vitro* diagnostic use only.
- Do not use after the expiration date indicated on the package. Do not use the test if the foil pouch is damaged. Do not reuse tests.
- This kit contains products of animal origin. Certified knowledge of the origin and/or sanitary state of the animals does not completely guarantee the absence of transmissible pathogenic agents. It is therefore recommended that these products be treated as potentially infectious, and handled by observing usual safety precautions (e.g., do not ingest or inhale).
- Read the entire procedure carefully prior to testing.
- Do not eat, drink or smoke in any area where specimens and kits are handled.
- Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout the procedure and follow standard procedures for the proper disposal of specimens. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are assayed.
- Do not interchange or mix reagents from different lots. Do not mix solution bottle caps.
- Humidity and temperature can adversely affect results.

## SPECIMEN COLLECTION AND PREPARATION

- The D-Dimer Rapid Test Cassette (Whole Blood/Plasma) is intended for use with human whole blood or plasma specimens only.
- Only clear, non-hemolyzed specimens are recommended for use with this test. Whole blood or Plasma should be separated as soon as possible to avoid hemolysis.
- Perform testing immediately after specimen collection. Do not leave specimens at room temperature for prolonged periods. Plasma specimens may be stored at 2-8°C for up to 3 days. For long term storage, specimens should be kept below -20°C. Whole blood collected by venipuncture should be stored at 2-8°C if the test is to be run within 2 days of collection. Do not freeze whole blood specimens. Whole blood collected by fingerstick should be tested immediately.
- Containers containing anticoagulants such as EDTA, citrate, or heparin should be used for whole blood storage.
- Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Avoid repeated freezing and thawing of specimens.

- If specimens are to be shipped, pack them in compliance with all applicable regulations for transportation of etiological agents.
- Icteric, lipemic, hemolysed, heat treated and contaminated specimens may cause erroneous results.

## TEST PROCEDURE

**Bring tests, specimens, reagents and/or controls to room temperature (15-30°C) prior to testing.**


- Remove the test cassette from the foil pouch and use it as soon as possible. Best results will be obtained if the assay is performed within one hour.
- Place the test cassette on a clean and level surface.

**For Whole Blood Specimen:** With the 10/20µL mini plastic dropper provided, draw the whole blood specimen to the upper scale line as showed in the following image and then transfer drawn whole blood into the sample well ( S ) of the test device., then add 2 drops of buffer (approximately 80µL) and start the timer. See illustration below.

**For Plasma Specimen:** With the 10/20µL mini plastic dropper provided, draw the plasma specimen to the bottom scale line as showed in the following image and then transfer drawn plasma into the sample well ( S ) of the test device. Then add 2 drops of buffer (approximately 80µL) and start the timer. See illustration below.

*Note: Practice a few times prior to testing if you are not familiar with the mini dropper. For better precision, transfer specimen by pipette capable to deliver 10 and 20µL of volume.*

- As the test begins to work, color will migrate across the membrane.
- Wait for the colored band(s) to appear. The result should be read in 10 minutes. Do not interpret the result after 15 minutes.



## INTERPRETATION OF RESULTS

(Please refer to the illustration above)

**Positive:** Two lines appear. One colored line should be in the control line region (C) and another apparent colored line should be in the test line region (T).

**Negative:** One colored line appears in the control line region(C). No line appears in the test line region (T).

**Invalid:** Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test Cassette. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

## QUALITY CONTROL

A procedural control is included in the test. A red line appearing in the control region (C) is the internal procedural control. It confirms sufficient specimen volume and correct procedural technique. Control standards are not supplied with this test. However, it is recommended that positive and negative controls are sourced from a local competent authority and tested as a good laboratory practice, to confirm the test procedure and verify the test performance.

## LIMITATIONS

- The D-Dimer Rapid Test Cassette (Whole Blood/Plasma) is for *in vitro* diagnostic use only. This test should be used for the detection of D-dimer in whole blood or plasma specimens only. Neither the quantitative value nor the rate of increase in D-dimer can be determined by this qualitative test.
- The D-Dimer Rapid Test Cassette (Whole Blood/Plasma) will only indicate the qualitative level of D-dimer in the specimen and should not be used as the sole criteria for the diagnosis of Disseminated Intravascular Coagulopathy (DIC), Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).
- During the process of serum is formed, also fibrinogen is converted to fibrin by the activation of thrombin and it also can be detected by D-dimer antibody. So serum specimen can't be used for D-Dimer Rapid Test Device (Whole Blood/Plasma).
- The D-Dimer Rapid Test Cassette (Whole Blood/Plasma) cannot detect less than 500 ng/mL D-dimer in specimens. A negative result at any time does not preclude the possibility of Disseminated Intravascular Coagulopathy (DIC), Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).
- False negative readings can occur if the sample is taken either too early after thrombus formation, if testing is delayed for several days or if the sample was take too later after the occurrence of thromboembolic infarction, because the D-dimer concentration may decrease to normal values after one week already. Additionally, a treatment with anti-coagulants prior sample collection can render the test negative because it prevents thrombus extension.
- As with all diagnostic tests, all results must be interpreted together with other clinical information available to the physician. E.g. use "Wells score" for DVT resp. PE, Ultrasound, quantitative laboratory D-Dimer results etc.
- Some specimens containing unusually high titers of heterophile antibodies or rheumatoid factor (RF) may affect expected results. Even if the test results are positive, further clinical evaluation should be considered with other clinical information available to the physician

## PERFORMANCE CHARACTERISTICS

### 1. Sensitivity and Specificity

The D-Dimer Rapid Test Cassette (Whole Blood/Plasma) has been evaluated with a leading commercial D-dimer EIA test using clinical specimens. The results show that the sensitivity of the D-Dimer Rapid Test Cassette (Whole Blood/Plasma) is 98.6% and the specificity is 98.6% relative to the leading EIA test.

Method	EIA			Total Results
	Results	Positive	Negative	
	Positive	71	3	
D-Dimer Rapid Test Cassette	Negative	1	211	212
Total Results		72	214	286

Relative Sensitivity: 98.6%

Relative Specificity: 98.6%

Accuracy: 98.6%

### 2. Precision

Within-run precision has been determined by using 15 replicates of below five specimens: D-dimer specimen levels at 0 ng/mL, 500 ng/mL, 1,000 ng/mL, 1,500 ng/mL and 3,000 ng/mL. The specimens were correctly identified at the prescribed reading time.

### 3. Inter-Assay

Between-run precision has been determined by 3 independent assays on the same five specimens: 0 ng/mL, 500 ng/mL, 1,000ng/mL, 1,500 ng/mL and 3,000 ng/mL of D-dimer. Three different lots of the D-Dimer Rapid Test Cassette (Whole Blood/Plasma) have been tested using these specimens. The specimens were correctly identified at the prescribed reading time.

### 4. Cross-reactivity

The D-Dimer Rapid Test Cassette (Whole Blood/Plasma) has been tested with HBsAg, HBsAb, HBeAg, HBeAb, HBcAb, anti-syphilis, anti-HIV, anti-H.pylori, IM heterophile antibodies, anti-CMV, anti-Rubella and anti-Toxoplasma positive specimens. The results showed no cross-reactivity.

### 5. Interfering Substances

The following potentially interfering substances were added to D-dimer negative and positive specimens, respectively.

Substances	Concentration
Acetaminophen	20 mg/dL
Caffeine	20 mg/dL
Acetylsalicylic Acid	20 mg/dL
Gentisic Acid	20 mg/dL
Ascorbic Acid	20 mg/dL
Albumin	10,500 mg/dL
Creatin	200 mg/dL
Hemoglobin	1,000 mg/dL
Bilirubin	1,000 mg/dL
Oxalic Acid	600 mg/dL
Cholesterol	800 mg/dL
Triglycerides	1,600 mg/dL

None of the substances at the concentration tested interfered in the assay.

## REFERENCE

- Gaffney, P.J. D-dimer History of Discovery, Characterisation and Utility of this and other Fibrin Fragments. Fibrinolysis 7 Suppl 2:2-8; 1993
- Lane, D.A. et al. Characterisation of Serum Fibrinogen and Fibrin Fragments Produced During Disseminated Intravascular Coagulation. Haematology. 40: 609-615; 1978.
- Scarvelis, D and Wells, P.S. Diagnosis and Treatment of Deep Vein Thrombosis. Can. Med. Assoc. J. 175 (9):1087-92; 2006
- Bick, R.L. et al. Diagnostic Efficacy of the D-dimer assay in Disseminated Intravascular Coagulation (DIC) Thromb. Res. 65:785-790; 1992.
- Bick, R.L. et al. Disseminated Intravascular Coagulation: Objective Clinical and Laboratory Diagnosis, Treatment, and Assessment of Therapeutic Response. Semin. Thromb. Hemost. 22(1): 69-88; 1996.
- Hunt, F.A. et al. Serum Cross-Linked Fibrin (XDP) and Fibrinogen/Fibrin Degradation Products (FDP) in Disorders Associated with Activation of the Coagulation or Fibrinolytic Systems. Br. J. Haematol. 60: 715-722; 1985.
- Subramanian, R.M. et. al. Does an Immunochromatographic D-dimer exclude acute lower limb deep venous thrombosis? Emer. Med. Austral. 18: 457-463; 2006.
- Runyon, M.S. et. al. Comparison of the Simplify D-dimer assay performed at the bedside with a laboratory based quantitative D-dimer assay for the diagnosis of pulmonary embolism in a low prevalence emergency department population. Emerg. Med. J. 25:70-75; 2008.

## INDEX OF SYMBOLS

	Consult instructions for use		Tests per kit		Authorized Representative
	For <i>in vitro</i> diagnostic use only		Use by		Do not reuse
	Store between 2~30°C		Lot Number		Catalog#



Zhejiang Orient Gene Biotech Co.,Ltd  
Address: 3787#, East Yangguang Avenue, Dipu Street,  
Anji 313300, Huzhou, Zhejiang, China  
Tel: +86-572-5226 111 Fax: +86-572-5226222  
Website: www.orientgene.com



QARAD BV  
Cipalstraat 3, 2440 Geel BELGIUM



GDDDI-402b

# HCV Hepatitis C Virus Rapid Test (Whole blood/Serum/Plasma)(Cassette)

CE 0123

REF GCHCV-402a

## INTENDED USE

The HCV Hepatitis C Virus Rapid Test (Whole blood/Serum/Plasma)(Cassette) is a sandwich lateral flow chromatographic immunoassay for the qualitative detection of antibodies (IgG, IgM, and IgA) to Hepatitis C virus (HCV) in human whole blood, serum or plasma. It is intended to be used as a screening test and as an aid in the diagnosis of infection with HCV. Any reactive specimen with the HCV Hepatitis C Virus Rapid Test Cassette must be confirmed with alternative testing method(s) and clinical findings.

## INTRODUCTION

Hepatitis C Virus (HCV) is a small, enveloped, positive-sense, single-stranded RNA virus. Antibody to HCV is found in over 80% of patients with well-documented non-A, non-B hepatitis. Conventional methods fail to isolate the virus in cell culture or visualize it by electron microscope. Cloning the viral genome has made it possible to develop serologic assays that use recombinant antigens (1, 2). Compared to the first generation HCV EIAs using single recombinant antigen, multiple antigens using recombinant protein and/or synthetic peptides have been added in new serologic tests to avoid nonspecific cross-reactivity and to increase the sensitivity of the HCV antibody tests (3, 4). HCV Hepatitis C Virus Rapid Test (Whole blood/Serum/Plasma)(Cassette) is a rapid test to qualitatively detect the presence of antibody to HCV in a whole blood, serum or plasma specimen. The test utilizes a combination of recombinant antigen to selectively detect elevated levels of HCV antibodies in whole blood, serum or plasma.

## PRINCIPLE

The HCV Hepatitis C Virus Rapid Test Cassette is a lateral flow chromatographic immunoassay based on the principle of the double antigen–sandwich technique. The test Cassette consists of: 1) a burgundy colored conjugate pad containing HCV antigens conjugated with colloidal gold (HCV Ag conjugates) and rabbit IgG-gold conjugates, 2) a nitrocellulose membrane Cassette containing a test band (T band) and a control band (C band). The T band is pre-coated with non-conjugated HCV antigens, and the C band is pre-coated with goat anti-rabbit IgG. When an adequate volume of test specimen is dispensed into the sample well of the Cassette, the specimen migrates by capillary action across the Cassette. The antibodies: either the IgG, the IgM, or the IgA, to HCV if present in the specimen will bind to the HCV Ag conjugates. The immunocomplex is then captured on the membrane by the precoated HCV antigens, forming a burgundy colored T band, indicating a HCV Ab positive test result. Absence of the T band suggests a negative result. The test contains an internal control (C band) which should exhibit a burgundy colored band of the immunocomplex of goat anti-rabbit IgG and rabbit IgG-gold conjugate regardless the presence of any antibodies to HCV. Otherwise, the test result is invalid and the specimen must be retested with another Cassette.

## PRODUCT CONTENTS

HCV Hepatitis C Virus Rapid Test (Whole blood/Serum/Plasma)(Cassette) containing HCV antigen (HCV antigen includes core, NS3, NS4 and NS5 segment) coated particles and HCV antigen (HCV recombinant antigen includes core, NS3, NS4 and NS5 segment) coated on the membrane.

## MATERIALS SUPPLIED

- 25 sealed pouches each containing a test cassette, a pipette dropper and a desiccant (Test Cassette T band is pre-coated with non-conjugated HCV antigens, and the C band is pre-coated with goat anti-rabbit IgG on the nitrocellulose and coupled to colloidal gold on label pad)
- 1 Package insert

- 1 Buffer (4 mL) (Casein-salt: 1%, NaCl: 0.9%, Na<sub>2</sub>HPO<sub>4</sub>: 0.286%, NaN<sub>3</sub>: 0.5%)



Warning

Warning: 0.5% NaN<sub>3</sub>  
Harmful if swallowed; Harmful to aquatic life with long lasting effects  
Prevention  
Wash face, hands and any exposed skin thoroughly after handling Wear protective gloves/protective clothing/eye protection/face protection  
Do not breathe dust/fume/gas/mist/vapors/spray  
Do not eat, drink or smoke when using this product  
Avoid release to the environment.  
Response  
IF SWALLOWED: rinse mouth. Do NOT induce vomiting.  
Get medical attention/advice if you feel unwell

## MATERIAL REQUIRED BUT NOT PROVIDED

- Specimen collection containers
- Sterile lancets (for fingerstick whole blood only)
- Centrifuge (for plasma only)
- Timer
- Heparinized capillary tubes and dispensing bulb (for fingerstick whole blood only)

## STORAGE AND STABILITY

The kit can be stored at room temperature or refrigerated (2-30°C). The test Cassette is stable through the expiration date printed on the sealed pouch. The test Cassette must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

## WARNINGS AND PRECAUTIONS

- For professional *in vitro* diagnostic use only. Do not use after expiration date.
- Warning: the reagents in this kit contain sodium azide which may react with lead or copper plumbing to form potentially explosive metal azides. When disposing of such reagents, always flush with large volumes of water to prevent azide build-up.
- Do not use it if the tube/pouch is damaged or broken.
- Test is for single use only. Do not re-use under any circumstances.
- Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout testing and follow the standard procedures for proper disposal of specimens.
- Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are assayed.
- Humidity and temperature can adversely affect results.
- Do not perform the test in a room with strong air flow, i.e. an electric fan or strong airconditioning.


## SPECIMEN COLLECTION

- The HCV Hepatitis C Virus Rapid Test (Whole Blood/Serum/Plasma) (Cassette) can be performed using whole blood (from venipuncture and fingerstick), serum or plasma.
- For venipuncture whole blood and plasma: K-EDTA, Sodium Heparin, Sodium citrate Sterile, and Lithium heparin should be used as the anticoagulant. Other anticoagulants have not been tested and may give incorrect results.
- To collect Fingerstick Whole Blood specimens:
  - Wash the patient's hand with soap and warm water or clean with an alcohol wipe . Allow to dry.
  - Massage the hand without touching the puncture site by rubbing down the hand towards the fingertip of the middle or ring finger.
  - Puncture the skin with a new sterile lancet for each person. Wipe away the first sign of blood.
  - Gently rub the hand from wrist to palm to finger to form a rounded drop of blood over the puncture site.
  - Add the Fingerstick Whole Blood specimen to the test device by using a capillary tube:
  - Touch the end of the capillary tube to the blood until filled to approximately 60 µL. Avoid air bubbles.
  - Place the bulb onto the top end of the capillary tube, then squeeze the bulb to dispense the whole blood into the specimen well (S) of the test device.
  - Separate serum or plasma from blood as soon as possible to avoid hemolysis. Use only clear, nonhemolyzed specimens.
- Testing should be performed immediately after specimen collection. Do not leave the specimens at room temperature for prolonged periods. Serum and plasma specimens may be stored at 2-8°C for up to 3 days and may be stored at -20°C for 6 months. Whole blood collected by venipuncture should be stored at 2-8°C if the test is to be run within 2 days of collection. Do not freeze whole blood specimens. Whole blood collected by fingerstick should be tested immediately.
- Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Specimens should not be frozen and thawed repeatedly.
- If specimens are to be shipped, they should be packed in compliance with usual regulations for transportation of etiological agents.

## TEST PROCEDURE

**Allow test cassette, specimen, buffer and/or controls to equilibrate to room temperature (15-30°C) prior to testing.**

- Remove the test Cassette from the foil pouch and use it as soon as possible. Best results will be obtained if the assay is performed within one hour.
- Place the test Cassette on a clean and level surface.  
**For Serum or Plasma Specimens:** Hold the dropper vertically and transfer 1 drop of serum or plasma (approximately 30 µL) to the specimen well (S) of the test Cassette, then add 1 drop of buffer (approximately 40 µL) and start the timer. See illustration below.  
**For Venipuncture Whole Blood Specimens:** Hold the dropper vertically and transfer 2 drops of venipuncture whole blood (approximately 60 µL) to the specimen well (S) of the test Cassette, then add 1 drop of buffer (approximately 40 µL) and start the timer. See illustration below.  
**For Fingerstick Whole Blood specimens:** To use a capillary tube: Fill the capillary tube and transfer approximately 60 µL of fingerstick whole blood specimen to the specimen well (S) of the test device, then add 1 drops of buffer (approximately 40 µL) and start the timer. See illustration below.
- Wait for the red line(s) to appear. The result should be read at 15 minutes. Do not interpret the result after 30 minutes.



INTERPRETATION OF RESULTS

(Please refer to the illustration above)

**Positive:** Two lines appear. One colored line should be in the control line region (C) and another apparent colored line should be in the test line region (T).

**Negative:** One colored line appears in the control line region (C). No line appears in the test line region (T).

**Invalid:** Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test Cassette. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

QUALITY CONTROL

A procedural control is included in the test. A red line appearing in the control region (C) is the internal procedural control. It confirms sufficient specimen volume and correct procedural technique. Control standards are not supplied with this test. However, it is recommended that positive and negative controls are sourced from a local competent authority and tested as a good laboratory practice, to confirm the test procedure and verify the test performance.

LIMITATIONS

1. The HCV Hepatitis C Virus Rapid Test (Whole blood/Serum/Plasma)(Cassette) is for *in vitro* diagnostic use only. This test should be used for the detection of antibodies to HCV in whole blood, serum or plasma specimen.
2. The HCV Hepatitis C Virus Rapid Test (Whole blood/Serum/Plasma)(Cassette) will only indicate the presence of antibodies to HCV in the specimen and should not be used as the sole criteria for the diagnosis of Hepatitis C viral infection.
3. As with all diagnostic tests, all results must be considered with other clinical information available to the physician.
4. If the test result is negative and clinical symptoms persist, additional follow-up testing using other clinical methods is recommended. A negative result at any time does not preclude the possibility of Hepatitis C Virus infection.
5. A negative result can occur if the quantity of the antibodies to HCV present in the specimen is below the detection limits of the assay, or the antibodies that are detected are not present during the stage of disease in which a sample is collected.
6. Some specimens containing unusually high titer of heterophile antibodies or rheumatoid factor may affect expected results.
7. As with all diagnostic tests, a definitive clinical diagnosis should not be based on the results of a single test, but should only be made by the physician after all clinical and laboratory findings have been evaluated.
8. Results should not be used to determine the genotype of HCV infections.
9. Due to possible cross reactivity, the appearance of lines in T line does not necessarily indicate co-infection from IgG, IgM or IgA, nor can it identify the serotype.
10. The recommended anticoagulants are K<sub>2</sub>EDTA, Sodium Heparin, Sodium citrate Sterile and Lithium heparin for venous whole blood. Other anticoagulants have not been evaluated with this test.

PERFORMANCE CHARACTERISTICS

Relative Sensitivity

A total of 506 HCV positive specimens were tested using the HCV Hepatitis C Virus Rapid Test (Whole blood/Serum/Plasma)(Cassette) and a commercially available test (Table 1). The relative sensitivity of the test is >99.9% (95% confidence interval: 99.27% – 100%).

**Table 1: Sensitivity of HCV Hepatitis C Virus Rapid Test (Whole blood/Serum/Plasma)(Cassette)**

Population	Specimen Type	Number of Specimens Tested	Positive by HCV Hepatitis C Virus Rapid Test	Positive by Commercially Available Test
Anti-HCV (any genotype)	plasma	329	329/329 (100%)	329/329 (100%)
Anti-HCV (any genotype)	Serum	26	26/26 (100%)	26/26 (100%)
Anti-HCV ( genotype 1, 2, 3, 4 (non-subtype A), 4, 5, 6)	Serum/Plasma	151	151/151 (100%)	151/151 (100%)
Total		506	506/506 (100%)	506/506 (100%)

30 Seroconversion panels have been done and details of the 30 seroconversion are in the table below.

No.	Panel	Specimens No.	Results
1	PHV907	7	Positive from 0 days since first bleed
2	PHV908	13	Positive from 3 days since first bleed
3	PHV206(M)	25	/
4	PHV911(M)	5	Positive from 3 days since first bleed
5	PHV919	7	Positive from 28 days since first bleed
6	PHV920	10, No. 2 can't be got because of out of stock from the vendor	Positive from 16 days since first bleed
7	HCV9047	10	Positive from 28 days since first bleed

8	HCV9046	5	Positive from 69 days since first bleed
9	HCV6229	8	Positive from 17 days since first bleed
10	HCV10041	3	Positive from 6 days since first bleed
11	HCV9041	8	Positive from 62 days since first bleed
12	HCV9045	8	Positive from 37 days since first bleed
13	HCV6222	3	Positive from 40 days since first bleed
14	HCV6224	8	Positive from 19 days since first bleed
15	HCV6227	7	Positive from 75 days since first bleed
16	HCV6228	12	Positive from 31 days since first bleed
17	HCV10071	7	Positive from 84 days since first bleed
18	HCV6220	6	Positive from 18 days since first bleed
19	HCV10185	5	Positive from 130 days since first bleed
20	HCV10235	5	Positive from 96 days since first bleed
21	HCV6215	4	Positive from 20 days since first bleed
22	HCV9042	6	Positive from 8 days since first bleed
23	HCV9058	5	Positive from 10 days since first bleed
24	HCV9094	5	Positive from 9 days since first bleed
25	HCV9095	5	Positive from 10 days since first bleed
26	HCV9055	11	Positive from 65 days since first bleed
27	HCV9054	10	Positive from 72 days since first bleed
28	HCV9044	6	Positive from 21 days since first bleed
29	HCV10165	9	Positive from 19 days since first bleed
30	HCV6226	12	Positive from 39 days since first bleed

Relative Specificity

A total of HCV 1259 negative specimens were tested using the HCV Hepatitis C Virus Rapid Test (Whole blood/Serum/Plasma)(Cassette) and a commercially available test (Table 2). The relative specificity of the test is >99.9% (95% confidence interval: 99.71% – 100%).

**Table 2: Specificity of the HCV Hepatitis C Virus Rapid Test (Whole blood/Serum/Plasma)(Cassette)**

Population	Specimens Tested	Number of Specimens Tested	Negative by HCV Hepatitis C Virus Rapid Test	Negative by Commercially Available Test
Clinical Negative	Serum/plasma	202	202/202 (100%)	202/202 (100%)
Potentially cross-reacting	Serum/Plasma	30	30/30 (100%)	30/30 (100%)
Unselected Donors	Serum	1000	1000/1000 (100%)	1000/1000 (100%)
Inhibition Panel	Serum	27	27/27 (100%)	27/27 (100%)
Total		1259	1259/1259 (100%)	1259/1259 (100%)

Whole Blood vs. Serum vs. Plasma

Total 25 clinical negative samples (whole blood, serum, plasma) have been collected from patients in local hospital. The whole blood collected and separated into three tubes. One was stored as whole blood. One was collected into tube for plasma, one was collected into tube for serum (Table 3). There is a very good correlation of results between whole blood, serum, and plasma with HCV negative samples.

**Table 3: A Comparison of HCV Hepatitis C Virus Rapid Test (Whole blood/Serum/Plasma)(Cassette) Specificity in negative Whole Blood and Paired Serum and Plasma Specimens**

Specimen Type	Number of Specimens Tested	Negative by HCV Ab
Serum	25	25/25 (100%)
Plasma	25	25/25 (100%)
Whole blood	25	25/25 (100%)



A total of 25 positive specimens (whole blood, serum, plasma) were tested using the HCV Hepatitis C Virus Rapid Test (Whole blood/Serum/Plasma)(Cassette) (Table 4). There is a very good correlation of results between whole blood and paired plasma with HCV positive samples.

**Table 4: A Comparison of HCV Hepatitis C Virus Rapid Test (Whole blood/Serum/Plasma)(Cassette) Specificity in positive Whole Blood and Paired Serum and Plasma Specimens.**

Specimen Type	Number of Specimens Tested	Positive by HCV Ab
Serum	25	25/25 (100%)
Plasma	25	25/25 (100%)
Whole blood	25	25/25 (100%)

#### Precision

##### Intra Assay

Within-run precision has been determined by using 20 replicates of four specimens: a negative, a low positive, medium positive and a high positive. The negative, low positive, medium positive and high positive values were correctly identified >99% of the time.

##### Inter-Assay

Between-run precision has been determined by 5 independent assays on the same four specimens: a negative, a low positive, medium positive and a high positive. Three different lots of the HCV Hepatitis C Virus Rapid Test (Whole blood/Serum/Plasma)(Cassette) have been tested using negative, low positive, medium positive and high positive specimens. The specimens were correctly identified >99% of the time.

#### Cross Reactivity

No cross-reactivity was observed when samples positive for other diseases such as HIV, Syphilis, Infectious Mononucleosis, HBV, Rheumatoid Factor, HAMA, Hyper IgG, Hyper IgM, anti-HAV, anti-HSV2, anti-HEV, anti-EBV and anti-CMV were tested.

#### Interfering Substances

No interference was observed in samples with high concentrations of Uric acid, Ascorbic Acid, Hemoglobin, Gentistic Acid, Acetaminophen, Oxalic Acid, Albumin, Caffeine, Bilirubin, EDTA, Aspirin and Methanol.


Analytes	Conc	Analytes	Conc
Control	0	Control	0
Uric acid	0.15 mg/mL	Albumin	20 mg/mL
Ascorbic Acid	0.2 mg/mL	Caffeine	0.2 mg/mL
Hemoglobin	5.0 mg/mL	Bilirubin	0.3 mg/mL
Gentistic Acid	0.2 mg/mL	EDTA	0.2 mg/mL
Acetaminophen	1.0 mg/mL	Aspirin	0.2 mg/mL
Oxalic Acid	0.2 mg/mL	Methanol	1.0%


#### REFERENCE

1. Choo, Q.L., G.Kuo, A.J. Weiner, L.R. Overby, D.W. Bradley, and M. Houghton. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 189; 244: 359
2. Kuo, G., Q.L. Choo, H.J. Alter, and M. Houghton. An assay for circulating antibodies to a major etiologic Virus of human non-A, non-B hepatitis. Science 1989; 244: 362
3. Van der Poel, C.L., H.T.M. Cuypers, H.W. Reesink, and P.N. Lelie. Confirmation of hepatitis C Virus infection by new four-antigen recombinant immunoblot assay. Lancet 1991; 337: 317
4. Wilber, J.C. Development and use of laboratory tests for hepatitis C infection: a review. J. Clin. Immunoassay 1993; 16: 204

#### INDEX OF SYMBOLS

	Consult instructions for use		Tests per kit		Authorized Representative
	For <i>in vitro</i> diagnostic use only		Use by		Do not reuse
	Store between 2-30°C		Lot Number		Catalog #
	Manufacturer		Warning		

 Healgen Scientific Limited Liability Company  
Address: 3818 Fuqua Street, Houston, TX 77047, USA.  
Tel: +1 713-733-8088 Fax: +1 713-733-8848  
Website: www.healgen.com

 QARAD b.v.b.a.  
Cipalstraat 3, B-2440 Geel, Belgium

# Troponin I

## Troponin I Rapid Test Cassette (Whole Blood/Serum/Plasma)

### Package Insert

A rapid visual immunoassay for the qualitative presumptive detection of cardiac Troponin I in human whole blood, serum, or plasma specimens.  
For professional *in vitro* diagnostic use only.

#### INTENDED USE

The Troponin I Rapid Test Cassette (Whole Blood/Serum/Plasma) is a rapid visual immunoassay for the qualitative presumptive detection of cardiac Troponin I in human whole blood, serum, or plasma specimens. This kit is intended to be used as an aid in the diagnosis of myocardial infarction (MI).

#### SUMMARY

Cardiac Troponin I (cTnI) is a protein found in cardiac muscle with a molecular weight of 22.5 kDa.<sup>1</sup> Troponin I is part of a three subunit complex comprising of Troponin T and Troponin C. Along with tropomyosin, this structural complex forms the main component that regulates the calcium sensitive ATPase activity of actomyosin in striated skeletal and cardiac muscle.<sup>2</sup> After cardiac injury occurs, Troponin I is released into the blood 4-6 hours after the onset of pain. The release pattern of cTnI is similar to CK-MB, but while CK-MB levels return to normal after 72 hours, Troponin I remains elevated for 6-10 days, thus providing for a longer window of detection for cardiac injury. The high specificity of cTnI measurements for the identification of myocardial damage has been demonstrated in conditions such as the perioperative period, after marathon runs, and blunt chest trauma.<sup>3</sup> cTnI release has also been documented in cardiac conditions other than acute myocardial infarction (AMI) such as unstable angina, congestive heart failure, and ischemic damage due to coronary artery bypass surgery.<sup>4</sup> Because of its high specificity and sensitivity in the myocardial tissue, Troponin I has recently become the most preferred biomarker for myocardial infarction.<sup>5</sup>

#### PRINCIPLE

The Troponin I Rapid Test Cassette (Whole Blood/Serum/Plasma) has been designed to detect cardiac Troponin I through visual interpretation of color development in the strip. The membrane was immobilized with anti-cTnI antibodies on the test region. During the test, the specimen is allowed to react with colored anti-cTnI antibodies colloidal gold conjugates, which were precoated on the sample pad of the test. The mixture then moves on the membrane by a capillary action, and interact with reagents on the membrane. If there were enough cTnI in specimens, a colored band will form at the test region of the membrane.

Presence of this colored band indicates a positive result, while its absence indicates a negative result. Appearance of a colored band at the control region serves as a procedural control. This indicates that proper volume of specimen has been added and membrane wicking has occurred.

#### PRECAUTIONS

1. For professional *in vitro* diagnostic use only.
2. Warning: the reagents in this kit contain sodium azide which may react with lead or copper plumbing to form potentially explosive metal azides. When disposing of such reagents, always flush with large volumes of water to prevent azide build-up.
3. Do not use it if the tube/pouch is damaged or broken.
4. Test is for single use only. Do not re-use under any circumstances.
5. Handle all specimens as if they contain infectious agents. Observe established standard procedure for proper disposal of specimens
6. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are assayed.
7. Humidity and temperature can adversely affect results.

#### STORAGE AND STABILITY

All reagents are ready to use as supplied. Store unused test device unopened at 2°C-30°C. If stored at 2°C-8°C, ensure that the test device is brought to room temperature before opening. The test is not stable out off the expiration date printed on the sealed pouch. Do not freeze the kit or expose the kit over 30°C.

#### SPECIMEN COLLECTION AND PREPARATION

- The Troponin I Rapid Test Cassette (Whole Blood/Serum/Plasma) is intended only for use with human whole blood, serum, or plasma specimens.
- Only clear, non-hemolyzed specimens are recommended for use with this test.
- Serum or plasma should be separated with soonest possible opportunity to avoid hemolysis.
- Perform the testing immediately after the specimen collection. Do not leave the specimens at room temperature for prolonged periods. Specimens may be stored at 2-8°C for up to 3 days. For long term storage, specimens should be kept below -20°C.
- Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Avoid repeated freezing and thawing of specimens.
- Pack the specimens in compliance with applicable regulations for transportation of etiological agents, in case they need to be shipped.
- Icteric, lipemic, hemolyzed, heat treated and contaminated sera may cause erroneous results.
- There is a slight possibility that some whole blood specimens with very high viscosity or which have been stored for more than 2 days may not run properly on the test device. Repeat the test with a serum or plasma specimen from the same patient using a new test device.

#### Materials Provided

1. Test cassettes
2. Disposable Droppers
3. Package insert

#### Materials Required But Not Provided

1. Specimen collection containers
2. Centrifuge (for plasma only)
3. Clock or Timer

#### DIRECTIONS FOR USE

Allow test device, specimen, buffer and/or controls to equilibrate to room temperature (15-30°C) prior to testing.

1. Remove the test from its sealed pouch, and place it on a clean, level surface. Label the device with patient or control identification. To obtain a best result, the assay should be performed within one hour.
2. Transfer **2-3 drops of serum or plasma** to the specimen well(S) of the device with a disposable pipette provided in the kit, and then start the timer.


#### OR

Transfer **4 drops of whole blood** specimen to the specimen well(S) of the device with a disposable pipette provided in the kit, and then start the timer.

#### OR

Allow **4 hanging drops of fingerstick whole blood** specimen to fall into the center of the specimen well (S) of the device, and then start the timer. Avoid trapping air bubbles in the specimen well (S), and do not drop any solution in observation window. As the test begins to work, you will see color move across the membrane.

2. Wait for the colored band(s) to appear. The result should be read at 15 minutes. Do not interpret the result after 20 minutes.



#### INTERPRETATION OF RESULTS

(Please refer to the illustration above)

**POSITIVE:** Two colored bands appear on the membrane. One band appears in the control region (C) and another band appears in the test region (T).

**NEGATIVE:** Only one colored band appears in the control region (C). No apparent colored band appears in the test region (T).

**INVALID:** Control band fails to appear. Results from any test which has not produced a control band at the specified reading time must be discarded.

Please review the procedure and repeat with a new test. If the problem persists, discontinue using the kit immediately and contact your local distributor.

**NOTE:** Insufficient specimen volume, incorrect operation procedure, or performing expired tests are the most likely reasons for control band failure.

#### QUALITY CONTROL

Internal procedural controls are included in the test. A colored band appearing in the control region (C) is considered an internal positive procedural control. It confirms sufficient specimen volume and correct procedural technique.

External controls are not supplied with this kit. It is recommended that positive and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.

#### LIMITATIONS

1. The Troponin I Rapid Test Cassette (Whole Blood/Serum/Plasma) is for professional *in vitro* diagnostic use, and should be used for the qualitative detection of cardiac Troponin I only. There is no meaning attributed to linen color intensity or width.
2. The Troponin I Rapid Test Cassette (Whole Blood/Serum/Plasma) will only indicate the presence of Troponin I in the specimen and should not be used as the sole criteria for the diagnosis of tuberculosis.
3. If the test result is negative and clinical symptoms persist, additional testing using other clinical methods is recommended. The test cannot detect less than 0.5 ng/mL of cTnI in specimens. Thus, a negative result does not at anytime rule out the existence of Troponin I in blood, because the antibodies may be absent or below the minimum detection level of the test.
4. Like with all diagnostic tests, a confirmed diagnosis should only be made by a physician after all clinical and laboratory findings have been evaluated.
5. Some specimens containing unusually high titers of heterophile antibodies or rheumatoid factor (RF) may affect expected results. Even if the test results are positive, further clinical evaluation should be considered with other clinical information available to the physician.

#### PERFORMANCE CHARACTERISTICS

Table: Troponin I Rapid Test vs. EIA

Method		Troponin I Rapid Test Cassette		Total Results
		Positive	Negative	
EIA	Positive	138	2	140
	Negative	1	315	316
Total Results		139	317	456

Relative Sensitivity: 98.6% (94.9%-99.8%)\*

Relative Specificity: 99.7% (98.3%-99.9%)\*

Overall Agreement: 99.3% (98.1%-99.9%)\*

\*95% Confidence Interval

#### BIBLIOGRAPHY

1. Adams, et al. Biochemical markers of myocardial injury, Immunoassay Circulation 88:750-763, 1993.
2. Mehegan JP, Tobacman LS. Cooperative interaction between troponin molecules bound to the cardiac thin filament. J.Biol.Chem. 266:966, 1991.
3. Adams, et al. Diagnosis of Perioperative myocardial infarction with measurements of cardiac troponin I. N.Eng.J.Med 330:670, 1994.
4. Hossein-Nia M, et al. Cardiac troponin I release in heart transplantation. Ann. Thorac.Surg. 61: 227, 1996.
5. Alpert JS, et al. Myocardial Infarction Redefined, Joint European Society of Cardiology American College of Cardiology: J. Am. Coll. Cardio., 36(3):959, 2000.